US20150202154A1 - Lipid membrane structure having intranuclear migrating property - Google Patents
Lipid membrane structure having intranuclear migrating property Download PDFInfo
- Publication number
- US20150202154A1 US20150202154A1 US14/617,525 US201514617525A US2015202154A1 US 20150202154 A1 US20150202154 A1 US 20150202154A1 US 201514617525 A US201514617525 A US 201514617525A US 2015202154 A1 US2015202154 A1 US 2015202154A1
- Authority
- US
- United States
- Prior art keywords
- lipid membrane
- membrane structure
- lipid
- polypeptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 284
- 239000012528 membrane Substances 0.000 title claims abstract description 246
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 133
- 210000004027 cell Anatomy 0.000 claims abstract description 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 108
- 229920001184 polypeptide Polymers 0.000 claims abstract description 106
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 76
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 76
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 75
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 57
- 239000000126 substance Substances 0.000 claims abstract description 34
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 239000002502 liposome Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 239000000427 antigen Substances 0.000 claims description 25
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 17
- 125000001165 hydrophobic group Chemical group 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 7
- 229920006317 cationic polymer Polymers 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 34
- 230000005012 migration Effects 0.000 abstract description 9
- 238000013508 migration Methods 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 238000006467 substitution reaction Methods 0.000 abstract description 8
- 238000012217 deletion Methods 0.000 abstract description 7
- 230000037430 deletion Effects 0.000 abstract description 7
- 238000003780 insertion Methods 0.000 abstract description 5
- 230000037431 insertion Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 64
- 108090000623 proteins and genes Proteins 0.000 description 62
- 108020004414 DNA Proteins 0.000 description 54
- 238000000034 method Methods 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 52
- 239000000203 mixture Substances 0.000 description 50
- 210000004940 nucleus Anatomy 0.000 description 49
- -1 sphingomyelin Natural products 0.000 description 42
- 239000013612 plasmid Substances 0.000 description 31
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 28
- 230000004048 modification Effects 0.000 description 26
- 238000012986 modification Methods 0.000 description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 25
- 108060001084 Luciferase Proteins 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 239000005089 Luciferase Substances 0.000 description 21
- 241000737052 Naso hexacanthus Species 0.000 description 21
- 229920000642 polymer Polymers 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 210000004681 ovum Anatomy 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 239000002202 Polyethylene glycol Substances 0.000 description 16
- 229920001542 oligosaccharide Polymers 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 14
- 239000002671 adjuvant Substances 0.000 description 14
- 239000011521 glass Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 108010007568 Protamines Proteins 0.000 description 13
- 102000007327 Protamines Human genes 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 229940048914 protamine Drugs 0.000 description 13
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 12
- 102100026277 Alpha-galactosidase A Human genes 0.000 description 12
- 239000007995 HEPES buffer Substances 0.000 description 12
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 description 12
- 238000005056 compaction Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 229920001577 copolymer Polymers 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003125 aqueous solvent Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 108010038765 octaarginine Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 125000002091 cationic group Chemical group 0.000 description 7
- 210000001163 endosome Anatomy 0.000 description 7
- 238000007667 floating Methods 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229930182558 Sterol Natural products 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 150000003432 sterols Chemical class 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000000240 adjuvant effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004779 membrane envelope Anatomy 0.000 description 5
- 150000002772 monosaccharides Chemical class 0.000 description 5
- 210000000633 nuclear envelope Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 5
- 108010011110 polyarginine Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 5
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 4
- 101100258294 Arabidopsis thaliana SUV2 gene Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 4
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 4
- FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 description 4
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002525 ultrasonication Methods 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- PNXSUXRNBHUCSF-HSYVXBRLSA-N 107658-43-5 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)OC(=O)CC[C@@H](C(=O)N[C@@H](C)C(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C1C=NC=N1 PNXSUXRNBHUCSF-HSYVXBRLSA-N 0.000 description 3
- AKIVKIDZMLQJCH-UHFFFAOYSA-N 12738-64-6 Chemical group C=1C=CC=CC=1C(=O)OCC(C(C1OC(=O)C=2C=CC=CC=2)OC(=O)C=2C=CC=CC=2)OC1(OC1C(C(OC(=O)C=2C=CC=CC=2)C(OC(=O)C=2C=CC=CC=2)C(COC(=O)C=2C=CC=CC=2)O1)OC(=O)C=1C=CC=CC=1)COC(=O)C1=CC=CC=C1 AKIVKIDZMLQJCH-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 3
- 108010087294 GALA peptide Proteins 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- OCIBBXPLUVYKCH-QXVNYKTNSA-N alpha-maltohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-QXVNYKTNSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- FOMCONPAMXXLBX-MQHGYYCBSA-N isopanose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H](O)[C@H]([C@H](O)[C@@H](O)C=O)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOMCONPAMXXLBX-MQHGYYCBSA-N 0.000 description 3
- DJMVHSOAUQHPSN-UHFFFAOYSA-N malto-hexaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 DJMVHSOAUQHPSN-UHFFFAOYSA-N 0.000 description 3
- FJCUPROCOFFUSR-UHFFFAOYSA-N malto-pentaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 FJCUPROCOFFUSR-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 229920001281 polyalkylene Polymers 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSESWLKFTMBIPZ-UHFFFAOYSA-N 4'-O-glucosyl-beta-gentiobiose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OCC2C(C(O)C(O)C(O)O2)O)C(O)C1O QSESWLKFTMBIPZ-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 206010013183 Dislocation of vertebra Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 229920005603 alternating copolymer Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- FYGDTMLNYKFZSV-ZWSAEMDYSA-N cellotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ZWSAEMDYSA-N 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
- RNIXKIRFSWLVQV-LDQQUJRXSA-N chacotriose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](CO)OC1O RNIXKIRFSWLVQV-LDQQUJRXSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940105990 diglycerin Drugs 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 108091005601 modified peptides Proteins 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- XNBZPOHDTUWNMW-QVCHUJKCSA-N solatriose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)OC1O XNBZPOHDTUWNMW-QVCHUJKCSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 150000008501 α-D-glucopyranosides Chemical class 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- XEMQOSAADIAHGQ-UUWRZZSWSA-N (2R)-2-(2-carboxyethyl)-2-[dodecyl-[2-(trimethylazaniumyl)acetyl]amino]tetradecanoate Chemical compound CCCCCCCCCCCCN(C(=O)C[N+](C)(C)C)[C@@](C([O-])=O)(CCC(O)=O)CCCCCCCCCCCC XEMQOSAADIAHGQ-UUWRZZSWSA-N 0.000 description 1
- FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 description 1
- DPSWBCAAYVEQQC-OQRKSSCTSA-N (2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-2-[(2R,3R,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O[C@@H]3[C@H](O)[C@@H](O)C(O)O[C@@H]3CO)O[C@H](CO)[C@@H](O)[C@@H]2O[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O DPSWBCAAYVEQQC-OQRKSSCTSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- MBZYKEVPFYHDOH-BQNIITSRSA-N 24,25-dihydrolanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@]21C MBZYKEVPFYHDOH-BQNIITSRSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- NIBVDXPSJBYJFT-VBBCUDLLSA-N Planteose Natural products O(C[C@@H]1[C@H](O)[C@@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1 NIBVDXPSJBYJFT-VBBCUDLLSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 229920004892 Triton X-102 Polymers 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- LNRUEZIDUKQGRH-UHFFFAOYSA-N Umbelliferose Natural products OC1C(O)C(CO)OC1(CO)OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 LNRUEZIDUKQGRH-UHFFFAOYSA-N 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- FBJQEBRMDXPWNX-SMGIPPFUSA-N alpha-D-Galp-(1->6)-alpha-D-Galp-(1->6)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-SMGIPPFUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- DJMVHSOAUQHPSN-KZSASMRXSA-N maltohexaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 DJMVHSOAUQHPSN-KZSASMRXSA-N 0.000 description 1
- UYQJCPNSAVWAFU-KVXMBEGHSA-N maltotetraose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 UYQJCPNSAVWAFU-KVXMBEGHSA-N 0.000 description 1
- RXVWSYJTUUKTEA-CGQAXDJHSA-N maltotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 RXVWSYJTUUKTEA-CGQAXDJHSA-N 0.000 description 1
- FZWBNHMXJMCXLU-YRBKNLIBSA-N manninotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-YRBKNLIBSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- NIBVDXPSJBYJFT-ZQSKZDJDSA-N planteose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 NIBVDXPSJBYJFT-ZQSKZDJDSA-N 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035440 response to pH Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- SONHXMAHPHADTF-UHFFFAOYSA-M sodium;2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O SONHXMAHPHADTF-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- LNRUEZIDUKQGRH-YZUCMPLFSA-N umbelliferose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 LNRUEZIDUKQGRH-YZUCMPLFSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A61K47/48815—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by a specific adjuvant, e.g. cytokines or CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Definitions
- the present invention relates to a lipid membrane structure having intranuclear migrating property. More specifically, the present invention relates to a lipid membrane structure such as liposome that can easily migrate into the nucleus of an immunocyte, especially the nucleus of dendritic cell.
- MEND multifunctional envelope-type nano device
- a liposome In order to enhance the release of medicament from a liposome taken up into the endosome, a liposome has been proposed of which surface is modified with a peptide, GALA (Biochemistry, 26, pp. 2964-2972, 1987 for the peptide; Biochemistry, 43, pp. 5618-5623, 2004 for the liposome) and MEND (Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030).
- GALA Biochemistry, 26, pp. 2964-2972, 1987 for the peptide; Biochemistry, 43, pp. 5618-5623, 2004 for the liposome
- MEND Japanese Patent Unexamined Publication
- a liposome of which outer surface is modified with octaarginine International Patent Publication WO2005/32593; Journal of Controlled Release, 98, pp. 317-323, 2004
- a bilamellar liposome having a lipid membrane modified with a nucleus permeable peptide International Patent Publication WO2006/101201
- a liposome of which surface is modified with a monosaccharide such as galactose and mannose
- a nucleic acid encoding an antigenic protein can be introduced into the nucleus of an immunocyte, especially dendritic cell having an antigen-presenting action, a protein transcribed and translated from the nucleic acid in the dendritic cell can be presented as an antigen on the surface of the dendritic cell, and the host organism can acquire immunity against that protein. From such point of view, a technique for efficiently delivering a nucleic acid into the nucleus of immunocyte, such as dendritic cell has been desired.
- nucleic acid introduction efficiency is insufficient compared with introduction into other cells, for example, tumor cells and hepatic parenchymal cells.
- nucleic acid Before an introduced nucleic acid is finally expressed in the nucleus, the nucleic acid inevitably undergoes various intracellular kinetic processes such as uptake into cell, escape from endosome, migration into nucleus, and intranuclear transcription.
- nondividing cells such as dendritic cell, an intact double-layered nuclear membrane constantly exist, and it is estimated that this nuclear membrane inhibits the intranuclear migrating ability of the lipid membrane structure.
- nucleic acid in order to deliver a nucleic acid into the nucleus of dendritic cell by using a lipid membrane structure, it is a very important object how the nucleic acid successfully overcomes each of the aforementioned processes, especially, the barrier of the double-layered nuclear membrane.
- KALA peptide a polypeptide consisting of 27 amino acid residues
- this reference fails to suggest whether or not this peptide promotes intranuclear migration of a lipid membrane structure.
- An object of the present invention is to provide a means for efficiently delivering a nucleic acid into the nucleus of an immunocyte, especially dendritic cell having an antigen-presenting ability. More specifically, the object of the present invention is to provide a lipid membrane structure that can efficiently deliver a nucleic acid into the nucleus of an immunocyte such as dendritic cell.
- the inventors of the present invention attempted to introduce a nucleic acid enclosed in MEND modified with an octaarginine polypeptide as a functional polypeptide that can enhance nuclear migrating property (International Patent Publication WO2005/32593), or MEND modified with the GALA peptide as a functional polypeptide that imparts endosomal escaping ability (Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030) into dendritic cells, but almost no expression of a polypeptide from the nucleic acid was observed.
- MEND modified with an octaarginine polypeptide as a functional polypeptide that can enhance nuclear migrating property
- MEND modified with the GALA peptide as a functional polypeptide that imparts endosomal escaping ability
- T-MEND multilamllar lipid membrane structure
- the inventors of the present invention further conducted researches, and as a result, found that when a lipid membrane of a lipid membrane structure such as MEND encapsulating a nucleic acid was modified with KALA peptide, efficiency of nucleic acid introduction into the nuclei of immunocytes such as dendritic cells was remarkably increased.
- the present invention was accomplished on the basis of the aforementioned finding.
- the present invention thus provides a lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with the following polypeptide (a) and/or polypeptide (b):
- polypeptide consisting of the amino acid sequence of SEQ ID NO: 1;
- polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1, which polypeptide has an activity of promoting migration of the lipid membrane structure into a nucleus of a cell.
- the aforementioned lipid membrane structure wherein the lipid membrane structure is a liposome; the aforementioned lipid membrane structure, wherein the cell is an immunocyte, preferably dendritic cell; the aforementioned lipid membrane structure, wherein the polypeptides (a) and/or (b) are modified with a hydrophobic group, preferably stearyl group, cholesteryl group, or the like, and the hydrophobic group is inserted into the lipid membrane; the aforementioned lipid membrane structure, which has a polypeptide containing a plurality of contiguous arginine residues, preferably a polypeptide containing 4 to 20 contiguous arginine residues, more preferably a polypeptide consisting only of 4 to 20 contiguous arginine residues, most preferably octaarginine, on the surface thereof; the aforementioned lipid membrane structure, which has a polyalkylene glycol or
- any of the aforementioned lipid membrane structures wherein a substance to be delivered is encapsulated in the inside of the lipid membrane structure.
- the substance to be delivered is a nucleic acid, for example, a functional nucleic acid such as a nucleic acid containing a gene or an siRNA; the aforementioned lipid membrane structure, wherein the substance to be delivered is DNA; the aforementioned lipid membrane structure, wherein the DNA is a DNA ligated with a vector DNA that does not contain CpG; the aforementioned lipid membrane structure, wherein the DNA does not contain CpG, and the DNA is a DNA ligated with a vector DNA that does not contain CpG; the aforementioned lipid membrane structure, wherein the substance to be delivered is a nucleic acid encoding an antigen polypeptide to be presented on the surface of an immunocyte, preferably surface of dend
- the aforementioned lipid membrane structure which is used for introducing a nucleic acid encoding an antigen polypeptide to be presented on the surface of an immunocyte, preferably surface of dendritic cell, into a nucleus of the immunocyte; the aforementioned lipid membrane structure, which is for use in immunotherapy against the aforementioned antigen polypeptide; and the aforementioned lipid membrane structure, wherein the antigen polypeptide is a surface polypeptide specific to a cancer cell.
- the present invention also provides a pharmaceutical composition containing the above lipid membrane structure as an active ingredient, preferably a pharmaceutical composition containing a nucleic acid as a substance to be delivered.
- a method for delivering a nucleic acid into a nucleus of a cell preferably a nucleus of an immunocyte, more preferably a nucleus of dendritic cell, of a mammal including human in vivo, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating the nucleic acid inside thereof; and a method for presenting an antigen polypeptide on the surface of an immunocyte, preferably dendritic cell, in a mammal including human in vivo, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the antigen polypeptide inside thereof.
- a method for presenting in vivo an antigen polypeptide on the surface of an immunocyte, preferably dendritic cell, in a mammal including human for immunization against the antigen polypeptide which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the antigen polypeptide inside thereof, and a method for immunotherapy of a malignant tumor by presenting in vivo a surface polypeptide specific to a cancer cell on the surface of an immunocyte, preferably dendritic cell, in a mammal including human for immunization against the polypeptide, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the polypeptide inside thereof.
- the present invention further provide a polypeptide used for promoting migration of a lipid membrane structure into a nucleus of a cell, preferably a nucleus of an immunocyte, more preferably a nucleus of dendritic cell, which consists of the following polypeptide (a) and/or polypeptide (b):
- the lipid membrane structure provided by the present invention can efficiently migrate into a nucleus of an arbitrary cell, such as immunocytes including dendritic cell, and can effectively release an encapsulated substance such as nucleic acid in the nucleus to induce expression of a polypeptide encoded by the nucleic acid.
- a nucleic acid encoding a polypeptide is introduced into the nucleus of dendritic cell by using the lipid membrane structure of the present invention, the polypeptide transcribed and translated from the nucleic acid is presented on the surface of the dendritic cell, and the living host can acquire immunity against the polypeptide. Therefore, it becomes possible to perform effective immunotherapy against any desired polypeptides.
- the lipid membrane structure provided by the present invention also has a characteristic feature that the lipid membrane structure itself can exhibit an adjuvant action for dendritic cells and promote production of various cytokines. Therefore, by administering dendritic cells transformed with the lipid membrane structure provided by the present invention, exacerbation or proliferation of tumor can be remarkably suppressed irrespective of the presence or absence of an adjuvant, and by administering the lipid membrane structure encapsulating an antigen protein, cytotoxicity can be enhanced in vivo. Furthermore, the lipid membrane structure also has a characteristic feature that, where CpG sequence is eliminated if desired from the vector moiety of DNA to be encapsulated, and also from DNA encoding a protein to be expressed, gene expression efficiency is markedly improved.
- FIG. 1 This figure depicts expression efficiency obtained with MEND of which lipid membrane was modified with the polypeptide (a) (KALA).
- FIG. 2 This figure depicts gene expression efficiency obtained with tetralamellar cationic T-MEND and anionic T-MEND of which lipid membrane was modified with the polypeptide (a) (KALA).
- FIG. 3 This figure depicts the results of presentation of antigen molecules on the surfaces of dendritic cells, which antigen molecules were expressed by introducing a gene encoding the antigen molecule into the nuclei of the dendritic cells using the lipid membrane structure of the present invention.
- FIG. 4 This figure depicts the result that KALA modifying the surface of MEND has an adjuvant effect for dendritic cells.
- FIG. 5 This figure depicts the CTL activity of protein-enclosing KALA-modified liposomes.
- FIG. 6 This figure depicts a process of constructing a CpG-free plasmid DNA having a new multiple cloning site as the first step of the method for constructing the plasmid DNA (2) described in Example 6.
- FIG. 7 This figure depicts a process of incorporating the luciferase gene into CpG-free NEWmcs as the second step of the method for constructing the plasmid DNA (2) described in Example 6.
- FIG. 8 This figure depicts a process of removing the remained one CpG sequence as the third step of the method for constructing the plasmid DNA (2) described in Example 6.
- FIG. 9 This figure depicts the gene expression activity-enhancing effect of KALA-MEND obtained by modification of vector of introduction plasmid.
- FIG. 10 This figure depicts the result that MEND of which surface was modified with KALA showed high antitumor activity irrespective of the presence or absence of adjuvant.
- FIG. 11 This figure depicts antitumor effect obtained by administering MEND of which surface was modified with KALA after the tumor was formed.
- lipids constituting the lipid membrane structure of the present invention include, for example, phospholipids, glycolipids, sterols, saturated or unsaturated fatty acids, and the like.
- Examples of the phospholipids and phospholipid derivatives include, for example, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, cardiolipin, sphingomyelin, ceramide phosphorylethanolamine, ceramide phosphorylglycerol, ceramide phosphorylglycerol phosphate, 1,2-dimyristoyl-1,2-deoxyphosphatidylcholine, plasmalogen, phosphatidic acid, and the like, and one or more kinds of these can used independently or in combination.
- fatty acid residues of these phospholipids are not particularly limited, examples include saturated or unsaturated aliphatic acid residues having 12 to 20 carbon atoms, and specific examples include, for example, acyl groups derived from such a fatty acid as lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid. Further, a phospholipid derived from a natural product such as egg yolk lecithin and soybean lecithin can also be used.
- glycolipids examples include glyceroglycolipids (for example, sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, and glycosyl diglyceride), sphingoglycolipids (for example, galactosyl cerebroside, lactosyl cerebroside and ganglioside), and the like.
- glyceroglycolipids for example, sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, and glycosyl diglyceride
- sphingoglycolipids for example, galactosyl cerebroside, lactosyl cerebroside and ganglioside
- sterols examples include animal-derived sterols (for example, cholesterol, cholesterol succinate, lanosterol, dihydrolanosterol, desmosterol and dihydrocholesterol), plant-derived sterols (phytosterol) (for example, stigmasterol, sitosterol, campesterol and brassicasterol), microorganism-derived sterols (for example, thymosterol and ergosterol), and the like.
- animal-derived sterols for example, cholesterol, cholesterol succinate, lanosterol, dihydrolanosterol, desmosterol and dihydrocholesterol
- plant-derived sterols for example, stigmasterol, sitosterol, campesterol and brassicasterol
- microorganism-derived sterols for example, thymosterol and ergosterol
- saturated or unsaturated fatty acids examples include saturated or unsaturated fatty acids having 12 to 20 carbon atoms, such as palmitic acid, oleic acid, stearic acid, arachidonic acid, and myristic acid.
- Form of the lipid membrane structure is not particularly limited, and examples of the form in which lipid membrane structures are dispersed in an aqueous solvent include unilamella liposomes, multi-lamella liposomes, 0/W type emulsions, W/O/W type emulsions, spherical micelles, fibrous micelles, layered structures of irregular shapes and the like.
- Examples of preferred form of the lipid membrane structure of the present invention include liposomes. Although liposomes may be explained hereafter as a preferred embodiment of the lipid membrane structure of the present invention, the lipid membrane structure of the present invention is not limited to liposomes.
- the lipid membrane structure of the present invention is used for delivering a substance into a nucleus of a cell, and is characterized in that the lipid membrane is modified with the following polypeptide (a) and/or polypeptide (b): (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1; and (b) a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1, which polypeptide has an activity of promoting migration of the lipid membrane structure into a nucleus of a cell.
- polypeptide a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1
- the aforementioned polypeptide (a) represented by SEQ ID NO: 1 is a polypeptide consisting of 27 amino acid residues obtained by eliminating three amino acid residues from the C-terminus of the known polypeptide (WEAKLAKALAKALAKHLAKALAKALKACEA) consisting of 30 amino acid residues (henceforth this polypeptide may be called “KALA peptide” in this specification, Biochemistry, 36, pp. 3008-3017, 1997).
- this reference describes that the polypeptide can form a complex with a plasmid DNA using cationic charge of itself, the reference fails to describe whether or not this peptide promotes intranuclear migration of a lipid membrane structure.
- the known KALA peptide comprises the sequence of the functional polypeptide consisting of 30 amino acid residues called GALA peptide (Bioor. Med. Chem., 5, pp. 1883-1891, 1997) including substitution of a plurality of amino acid residues with other amino acid residues (for example, a plurality of glutamine residues are replaced by lysine residues).
- GALA peptide has a function of promoting fusion of lipid membranes in response to pH, and a function of enhancing ability of a lipid membrane structure to escape from the endosome, and these functions are different from the function of the KALA peptide used in the present invention (function of improving intranuclear migrating property of a lipid membrane structure in a cell).
- the polypeptide (b) a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1 (henceforth referred to as “modified polypeptide”), and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell may also be used.
- modified polypeptide a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1
- modified polypeptide a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1
- modified polypeptide a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1 (henceforth referred to as “mod
- the evaluation can be performed, for example, by preparing a lipid membrane structure wherein lipid membrane thereof is modified with the modified polypeptide (henceforth this lipid membrane structure is referred to as “modified lipid membrane structure”), and also by preparing a lipid membrane structure in which lipid membrane is not modified with the modified polypeptide (henceforth this lipid membrane structure is referred to as “unmodified lipid membrane structure”), and determining whether or not expression amount of the marker peptide in a cell introduced with the modified lipid membrane structure is increased compared with that of the marker peptide in a cell introduced with the unmodified lipid membrane structure.
- polypeptide (a) and polypeptide (b) can be biologically prepared by using a host cell with various kinds of gene recombination techniques available to those skilled in the art.
- the aforementioned polypeptides may also be prepared by an organic chemical method utilizing a peptide synthesis reaction available for those skilled in the art, such as the solid phase synthesis method. Alternatively, they may also be automatically synthesized by using a peptide synthesizer.
- the modification of the lipid membrane can be easily attained by, for example, modifying the aforementioned polypeptide (a) and/or polypeptide (b) with a hydrophobic group such as stearyl group or cholesteryl group, and preparing the lipid membrane structure so that the hydrophobic group is buried in the lipid membrane of the lipid membrane structure.
- a hydrophobic group such as stearyl group or cholesteryl group
- a residue of arbitrary hydrophobic compound can be used.
- the modification of lipid membrane with the aforementioned polypeptide (a) and/or polypeptide (b) may be performed for an inner lipid membrane as well as for an outer lipid membrane.
- the lipid membrane structure of the present invention can be used for delivering a substance into a nucleus of a cell.
- Type of the cell is not particularly limited, and an arbitrary cell can be used as the target depending on a type of the substance to be delivered, purpose of the delivery of substance into the nucleus, and the like.
- Preferred examples of the cell to be the target include immunocytes, and among immunocytes, antigen-presenting cells are preferably used.
- antigen-presenting cells such as macrophage, dendritic cell, and B cell are preferred, and dendritic cell is particularly preferred.
- surface of the lipid membrane structure can also be modified with, for example, a tri- or higher oligosaccharide compound.
- a tri- or higher oligosaccharide compound is not particularly limited, for example, an oligosaccharide compound comprising about 3 to 10 of linked saccharide units can be used, and an oligosaccharide compound comprising about 3 to 6 of linked saccharide units can be preferably used.
- examples of the oligosaccharide compound include, for example, trisaccharide compounds such as cellotriose ( ⁇ -D-glucopyranosyl-(1->4)- ⁇ -D-glucopyranosyl-(1->4)-D-glucose), chacotriose ( ⁇ -L-rhamnopyranosyl-(1->2)-[ ⁇ -L-rhamnopyranosyl-(1->4)]-D-glucose), gentianose ( ⁇ -D-fructofuranosyl- ⁇ -D-glucopyranosyl-(1->6)- ⁇ -D-glucopyranoside), isomaltotriose ( ⁇ -D-glucopyranosyl-(1->6)- ⁇ -D-glucopyranosyl-(1->6)-D-glucose), isopanose ( ⁇ -D-glucopyranosyl-(1->4)-[ ⁇ -D-glucopyranosyl-
- Oligosaccharide compounds as trimer to hexamer of glucose can be preferably used, and oligosaccharide compounds as trimer or tetramer of glucose can be more preferably used. More specifically, isomalttriose, isopanose, maltotriose, maltotetraose, maltopentaose, maltohexaose, and the like can be preferably used, and among these, maltotriose, maltotetraose, maltopentaose, and maltohexaose consisting of glucose units linked through ⁇ 1-4 linkages are more preferred. Particularly preferred are maltotriose and maltotetraose, and most preferred is maltotriose.
- amount of the oligosaccharide compound used for the surface modification of the lipid membrane structure is not particularly limited, it is, for example, about 1 to 30 mol %, preferably about 2 to 20 mol %, more preferably about 5 to 10 mol %, based on the total amount of lipids.
- the method for modifying the surface of the lipid membrane structure with the oligosaccharide compound is not particularly limited, for example, since liposomes consisting of lipid membrane structures of which surfaces are modified with monosaccharides such as galactose and mannose are known (International Patent Publication WO2007/102481), the surface modification method described in this publication can be employed.
- the entire disclosure of the aforementioned publication is incorporated into the disclosure of this specification by reference. This means is a method of binding a monosaccharide compound to polyalkylene glycolated lipids to perform surface modification of lipid membrane structures. Since surfaces of lipid membrane structures can be simultaneously modified with polyalkylene glycol by this means, it is preferred.
- Blood retainability of a liposome can be enhanced by modifying the surface of the lipid membrane structure as the liposome with a hydrophilic polymer such as polyalkylene glycol.
- a hydrophilic polymer such as polyalkylene glycol.
- a polyalkylene glycol is preferred.
- polyalkylene glycol for example, polyethylene glycol, polypropylene glycol, polytetramethylene glycol, polyhexamethylene glycol, and the like can be used.
- Molecular weight of the polyalkylene glycol is, for example, about 300 to 10,000, preferably about 500 to 10,000, more preferably about 1,000 to 5,000.
- the surface modification of the lipid membrane structure with a polyalkylene glycol can be easily performed by constructing the lipid membrane structure using, for example, a polyalkylene glycol-modified lipid as a lipid membrane-constituting lipid.
- a polyalkylene glycol-modified lipid as a lipid membrane-constituting lipid.
- stearylated polyethylene glycols for example, PEG45 stearate (STR-PEG45) and the like
- PEG45 stearylated polyethylene glycols
- polyethylene glycol derivatives such as N- ⁇ carbonyl-methoxypolyethylene glycol 2000 ⁇ -1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, n- ⁇ carbonyl-methoxypolyethylene glycol 5000 ⁇ -1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, N- ⁇ carbonyl-methoxypolyethylene glycol 750 ⁇ -1,2-distearoyl-sn-glycero-3-phosphoethanolamine, N- ⁇ carbonyl-methoxypolyethylene glycol 2000 ⁇ -1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and N- ⁇ carbonyl-methoxypolyethylene glycol 5000 ⁇ -1,2-distearoyl-sn-glycero-3-phosphoethanolamine, can also be used.
- the polyalkylene glycolated lipid is not limited to these.
- the surface modification of the lipid membrane structure can also be performed with, for example, the aforementioned polypeptide (a) and/or polypeptide (b) modified with a polyalkylene glycol.
- the aforementioned polypeptide (a) and/or polypeptide (b) modified with a polyalkylene glycol condensed with an appropriate phospholipid, for example, a stearylated polyethylene glycol can be used.
- the modifications of the lipid membrane with a polyalkylene glycol and the aforementioned polypeptide (a), and/or polypeptide (b) can be simultaneously attained.
- the method for modifying the surface of the lipid membrane structure with a polyalkylene glycol or an oligosaccharide compound is not limited to the aforementioned method.
- the surface modification may be performed by using a lipidated compound such as a stearylated polyalkylene glycol or oligosaccharide compound as a constituent lipid of the lipid membrane structure.
- lipid derivatives for enhancing retainability in blood used for the preparation of the lipid membrane structure of the present invention for example, glycophorin, ganglioside GM1, phosphatidylinositol, ganglioside GM3, glucuronic acid derivative, glutamic acid derivative, polyglycerin-phospholipid derivative, and the like can be used.
- hydrophilic polymer for enhancing retainability in blood besides polyalkylene glycol, dextran, pullulan, Ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymer, divinyl ether-maleic anhydride alternating copolymer, amylose, amylopectin, chitosan, mannan, cyclodextrin, pectin, carrageenan, and the like can also be used for the surface modification.
- the lipid membrane of the lipid membrane structure of the present invention may be modified with GALA.
- GALA lipid membrane structure of which surfaces are modified with GALA
- the lipid membrane structure of which surface is modified with GALA can be easily prepared according to the method described in the aforementioned publication.
- a lipid membrane structure of which surface is modified with GALA can be prepared.
- amount of GALA used for the surface modification of the lipid membrane structure is not particularly limited, it is, for example, about 0.01 to 10 mol %, preferably about 0.1 to 4 mol %, more preferably about 1 to 3 mol %, based on the total amount of lipids.
- GALA referred to in this specification include the peptide specified by SEQ ID NO: 1 mentioned in Sequence Listing of Japanese Patent Unexamined Publication (KOKAI) No. 2006.28030, as well as a modified peptide thereof having the amino acid sequence of the aforementioned peptide, but including deletion, substitution and/or addition of one or several amino acid residues, and having substantially the same properties as those of GALA (for example, a property that it can fuse lipid membranes under an acid condition).
- the term “GALA” used in this specification should not be construed in any limitative way.
- GALA and method for surface modification of a lipid membrane structure with GALA the entire disclosure of Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030 is incorporated into the disclosure of this specification by reference.
- the MPC polymer is an MPC polymer obtainable by polymerizing 2-methacryloyloxyethylphosphorylcholine (MPC). It has been demonstrated that, since this polymer has a molecular structure similar to that of biomembranes, it scarcely shows interactions with biological substances such as polypeptides and hemocytes, and shows superior biocompatibility.
- MPC polymer is used for referring to both a homopolymer of MPC and a copolymer of MPC and another polymerization component.
- MPC polymer commercial polymers can be easily obtained.
- a homopolymer of MPC (CAS: 67881-99-6); a copolymer of MPC with butyl methacrylate (CAS: 125275-25-4); a terpolymer of MPC, sodium methacrylate and butyl methacrylate; a bipolymer of MPC and 2-hydroxy-3-(meth)acryloyloxypropyltrimethylammonium chloride; a phospholipid polymer (LIPIDURE-S), and the like are provided by NOF Corporation with the registered trademark of “LIPIDURE”, and any of these can be used for the present invention.
- type of the MPC polymer used for the present invention is not particularly limited, for example, a copolymer of MPC and a methacrylic acid ester such as butyl methacrylate, especially such a block copolymer, and the like can be preferably used.
- the preparation method of this copolymer is described in detail in Japanese Patent No. 2890316, and those skilled in the art can easily prepare a desired copolymer by referring to this patent publication. The entire disclosure of this patent publication is incorporated into the disclosure of this specification by reference.
- an MPC polymer showing water solubility and having a hydrophobic group is preferably used.
- an MPC copolymer prepared by using an acrylic acid ester or methacrylic acid ester having about 4 to 18 carbon atoms can be preferably used.
- a copolymer of MPC and butyl methacrylate (BMA) for example, a copolymer having a molar ratio of MPC and BMA of 5:5 (PMB50), a copolymer having a molar ratio of MPC and BMA of 3:7 (PMB30), and the like are known, and it can be easily prepared according to, for example, the method described in Polymer Journal, 22, pp. 355-360, 1990, or the like (specific preparation methods are explained in, for example, Japanese Patent Unexamined Publication (KOKAI) No.
- PMB50 can be most preferably used.
- degree of polymerization and molecular weight of the MPC polymer are not particularly limited, a polymer having an average molecular weight (weight average molecular weight) of, for example, about 5,000 to 300,000, preferably about 10,000 to 100,000, can be used from a viewpoint of maintaining water solubility.
- an MPC polymer can be added to an aqueous dispersion of the lipid membrane structure such as liposomes, and the mixture can be left at room temperature for about several minutes to several hours.
- amount of the MPC polymer to be added to the aforementioned aqueous dispersion is not particularly limited, it may be added in an amount corresponding to the amount of the MPC polymer used for the modification, for example, 0.01 to 1 mass %, preferably about 0.1 to 10 mass %, more preferably about 0.1 to 3 mass %, based on the total amount of lipids of the lipid membrane structure.
- the MPC polymer is quickly taken up into the lipid components of the lipid membrane structure, and the lipid membrane structure of which surface is modified with the MPC polymer can be prepared.
- amount of the MPC polymer used for the surface modification is not particularly limited, it is, for example, in the range of about 0.1 to 5 mass % based on the total amount of lipids of the lipid membrane structure.
- the lipid membrane structure of the present invention may contain one or two or more kinds of substances selected from the group consisting of a membrane stabilization agent such as sterol, glycerol, and a fatty acid ester thereof, an antioxidant such as tocopherol, propyl gallate, ascorbyl palmitate, and butylated hydroxytoluene, a chargeable substance, a membrane polypeptide, and the like.
- a membrane stabilization agent such as sterol, glycerol, and a fatty acid ester thereof
- an antioxidant such as tocopherol, propyl gallate, ascorbyl palmitate, and butylated hydroxytoluene
- chargeable substance a membrane polypeptide, and the like.
- Examples of the chargeable substance that imparts positive charge include saturated or unsaturated fatty amines such as stearylamine and oleylamine; saturated or unsaturated synthetic cationic lipids such as dioleoyltrimethylammonium propane; cationic polymers, and the like, and examples of the chargeable substance that imparts negative charge include, for example, dicetyl phosphate, cholesteryl hemisuccinate, phosphatidylserine, phosphatidylinositol, phosphatidic acid, and the like.
- Examples of the membrane polypeptide include, for example, extrinsic membrane polypeptides, integral membrane polypeptides, and the like. Amounts of these substances to be added are not particularly limited, and can be appropriately chosen depending on the purpose.
- the lipid membrane structure of the present invention may be imparted with one or two or more functions selected from, for example, temperature change sensing function, membrane permeating function, gene expressing function, pH sensing function, and the like.
- one or two or more functions selected from, for example, temperature change sensing function, membrane permeating function, gene expressing function, pH sensing function, and the like.
- temperature change-sensitive lipid derivatives that can impart the temperature change sensing function include, for example, dipalmitoylphosphatidylcholine and the like.
- pH-sensitive lipid derivatives that can impart the pH sensing function include, for example, dioleoylphosphatidylethanolamine and the like.
- the lipid membrane structure of the present invention may also be modified with a substance that can specifically bind with a receptor or antigen on the surface of a cell, such as antibodies, to improve efficiency of delivery of a substance into the nucleus.
- a monoclonal antibody directed to a biological component specifically expressed in a target tissue or organ is preferably disposed on the surface of the lipid membrane structure.
- a lipid derivative that can react with mercapto group in a monoclonal antibody or a fragment thereof (e.g., Fab fragment, F(ab′)2 fragment, Fab′ fragment and the like), specifically, a lipid derivative having a maleinimide structure such as poly(ethylene glycol)- ⁇ -distearoylphosphatidylethanolamine- ⁇ -maleinimide and ⁇ -[N-(1,2-distearoyl-sn-glycero-3-phosphorylethyl)carbamyl]- ⁇ - ⁇ 3-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethanecarboxamido]propyl ⁇ -poly(oxy-1
- polyarginine a polypeptide containing a plurality of contiguous arginine residues
- polyarginine a polypeptide containing 4 to 20 contiguous arginine residues, more preferably a polypeptide consisting only of 4 to 20 contiguous arginine residues, most preferably octaarginine, and the like can be used.
- lipid membrane structure such as liposome
- a polyarginine such as octaarginine
- intracellular delivery efficiency of a target substance enclosed in liposome can be improved (Journal of Controlled Release, 98, pp. 317-323, 2004; International Patent Publication WO2005/32593).
- Surface of the lipid membrane structure can be easily modified with a polyarginine according to the method described in the aforementioned publications using, for example, a lipid-modified polyarginine such as stearylated octaarginine as a constituent lipid of the lipid membrane structure.
- INF7 is a glutamic acid-rich peptide obtained by modifying a peptide (1-23) derived from the influenza HA polypeptide (HA2), and it has been reported that the lipid structure of liposomes is collapsed in the presence of INF7, and a substance enclosed in the liposomes is easily released (Biochemistry, 46, pp. 13490-13504, 2007).
- a delivery system comprising polyethylene glycol tetraacrylate (PEG-TA) bound with INF7 (The Journal of Gene Medicine, 10, pp. 1134-1149, 2008).
- PEG-TA polyethylene glycol tetraacrylate
- INF7 used in this specification is used to refer to the peptide specified by the sequence described in Biochemistry, 46, pp. 13490-13504, 2007, Table 1, as well as a modified peptide thereof having the amino acid sequence of the aforementioned peptide, but including deletion, substitution and/or addition of one or several amino acid residues, and having substantially the same properties as those of INF7.
- the term “INF7” used in this specification should not be construed in any limitative way.
- the method for modifying the lipid membrane structure with INF7 is not particularly limited, the lipid membrane structure of which surface is modified with INF7 can generally be easily prepared by constructing the lipid membrane structure by using a lipid-modified INF7 comprising a lipid compound and INF7 covalently bound with each other as a lipid membrane constituent lipid.
- a lipid-modified INF for example, stearylated INF7 and the like can be used. This compound can be easily prepared according to the method described in Futaki, S. et al., Bioconjug. Chem., 12 (6), pp. 1005-1011, 2001.
- amount of INF7 used for the surface modification is not particularly limited, it is generally in the range of 1 to 5 mole %, preferably about 3 to 5 mole %, based on the total amount of lipids of the lipid membrane structure.
- a multifunctional envelope-type nano device is known, and it can be preferably used as the lipid membrane structure of the present invention.
- MEND has, for example, a structure that it contains a complex of a nucleic acid such as plasmid DNA and a cationic polymer such as protamine as a core, and the core is enclosed in the inside of a lipid envelope membrane in the form of liposome.
- a peptide for adjusting pH responding property and membrane permeability can be disposed as required, and the external surface of the lipid envelope membrane can be modified with an alkylene glycol such as polyethylene glycol.
- Condensed DNA and the cationic polymer are enclosed in the inside of the lipid envelope of MEND, and it is designed so that gene expression can be efficiently attained.
- MEND suitably used for the present invention, MEND in which a complex of a plasmid DNA incorporated with a desired gene and protamine is enclosed in the inside, and the outer surface of the lipid envelope is modified with an oligosaccharide-bound PEG is preferred.
- oligosaccharide-bound PEG it is preferable to use stearylated polyethylene glycol bound with the polypeptide (a) and/or the polypeptide (b) mentioned above as a constituent lipid component.
- references for general remarks such as Drug Delivery System, 22-2, pp. 115-122, 2007, can be referred to.
- the disclosure of the aforementioned publication and the disclosures of all of the references cited in this publication are incorporated into the disclosure of this specification by reference.
- lipid membrane structure is not particularly limited, examples include, for example, a dispersion in an aqueous solvent (for example, water, physiological saline, phosphate buffered physiological saline, and the like), a lyophilized product of the aqueous dispersion, and the like.
- an aqueous solvent for example, water, physiological saline, phosphate buffered physiological saline, and the like
- a lyophilized product of the aqueous dispersion and the like.
- the method for preparing the lipid membrane structure is not particularly limited, either, and an arbitrary method available for those skilled in the art can be employed.
- the lipid membrane structure can be prepared by dissolving all the lipid components in an organic solvent such as chloroform, forming a lipid membrane by exsiccation under reduced pressure in an evaporator or spray drying using a spray dryer, then adding an aqueous solvent to the aforementioned dried mixture, and emulsifying the mixture with an emulsifier such as homogenizer, an ultrasonic emulsifier, a high pressure injection emulsifier, or the like.
- an organic solvent such as chloroform
- forming a lipid membrane by exsiccation under reduced pressure in an evaporator or spray drying using a spray dryer
- an aqueous solvent to the aforementioned dried mixture
- emulsifier such as homogenizer, an ultrasonic emulsifier, a high pressure injection emulsifier, or the like.
- the dispersed lipid membrane structure is not particularly limited, in the case of liposome, for example, particle size is about 50 nm to 5 ⁇ m, preferably about 50 nm to 400 nm, more preferably 50 nm to 300 nm, still more preferably 150 nm to 250 nm.
- the particle size can be measured by, for example, the DLS (dynamic light scattering) method.
- composition of the aqueous solvent is not particularly limited, and examples include, for example, a buffer such as phosphate buffer, citrate buffer, and phosphate-buffered physiological saline, physiological saline, a medium for cell culture and the like.
- the solvents may be further added with a saccharide (aqueous solution), for example, a monosaccharide such as glucose, galactose, mannose, fructose, inositol, ribose and xylose, a disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose, a trisaccharide such as raffinose and melezitose, and polysaccharide such as cyclodextrin, a sugar alcohol such as erythritol, xylitol, sorbitol, mannitol, and maltitol, or a polyhydric alcohol (aqueous solution) such as glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene
- a saccharide aqueous solution
- a monosaccharide such as glucose, galact
- a saccharide for example, a monosaccharide such as glucose, galactose, mannose, fructose, inositol, ribose and xylose, a disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose, a trisaccharide such as raffinose and melezitose, a polysaccharide such as cyclodextrin, a sugar alcohol such as erythritol, xylitol, sorbitol, mannitol, and maltitol or the like may improve stability.
- a monosaccharide such as glucose, galactose, mannose, fructose, inositol, ribose and xylose
- a disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose
- a trisaccharide
- aqueous solution such as glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol mono-alkyl ether, diethylene glycol mono-alkyl ether and 1,3-butylene glycol may improve stability.
- a substance to be delivered to the inside of a nucleus of a cell in a target tissue or organ can be enclosed.
- type of the substance to be enclosed is not particularly limited, active ingredients of arbitrary medicaments such as antitumor agent, anti-inflammatory agent, antimicrobial agent, and antiviral agent as well as other arbitrary substances such as saccharides, peptides, nucleic acids, low molecular weight compounds, and metallic compounds can be enclosed.
- the nucleic acid include a nucleic acid containing a gene, and specific examples include, for example, a gene incorporated into a plasmid. However, the nucleic acid is not limited to these specific examples. Further, it is of course that arbitrary genes can be used as the gene. Although a case of enclosing a nucleic acid will be specifically explained below as an example of the present invention, the scope of the present invention is not limited to this specific embodiment.
- a nucleic acid in the lipid membrane structure of the present invention, can be preferably enclosed.
- the nucleic acid includes DNA and RNA, as well as analogues and derivatives thereof (for example, peptide nucleic acid (PNA), phosphorothioate DNA, and the like).
- the nucleic acid may be a single-stranded or double-stranded nucleic acid, and may be a linear or cyclic nucleic acid.
- the nucleic acid may contain a gene.
- the gene may be any of oligonucleotide, DNA, and RNA, and in particular, genes for in vitro induction such as transformation, genes acting after in vivo expression thereof, for example, genes for gene therapies such as normal genes for homologous recombination, and the like can be mentioned.
- nucleic acid for therapeutic treatment antisense oligonucleotide, antisense DNA, antisense RNA, and a gene encoding an enzyme or a physiologically active substance such as cytokine, as well as a nucleic acid having a function of controlling gene expression, for example, a functional nucleic acid including RNA such as siRNA can also be used, and these are also encompassed within the scope of the term “nucleic acid” used in this specification.
- the term “nucleic acid” used in this specification must be construed in its broadest sense, and it should not be construed in any limitative way.
- a gene DNA to be expressed can be ligated to a vector DNA, and encapsulated in the lipid membrane structure.
- the vector DNA does not contain any CpG sequence, and it may be more preferred that, in addition to the above, the gene DNA to be expressed does not contain any CpG sequence. It is preferred that an enhancer and/or a promoter is ligated to the vector.
- a compound having a nucleic acid-introducing function can also be added.
- examples of such a compound include, for example, O,O′—N-didodecanoly-N-( ⁇ -trimethylammonioacetyl)-diethanolamine chloride, O,O′—N-ditetradecanoly-N-( ⁇ -trimethylammonioacetyl)-diethanolamine chloride, O,O′—N-dihexadecanoly-N-( ⁇ -trimethylammonioacetyli-diethanolamine chloride, O,O′—N-dioctadecenoyl-N-( ⁇ -trimethylammonioacetyli-diethanolamine chloride, O,O′,O′′-tridecanoly-N-( ⁇ -trimethylammoniodecanoyl)aminomethane bromide, N-[ ⁇ -trimethylammoni
- the lipid membrane structure encapsulating a nucleic acid can be used as a carrier for delivering the nucleic acid into a nucleus of a cell of a target tissue or organ.
- a nucleic acid containing a desired gene as the nucleic acid and the aforementioned MEND.
- administering a lipid membrane structure, preferably MEND, enclosing a nucleic acid containing a gene to a mammal including human a desired gene can be delivered into nuclei of cells of a target tissue or organ, and efficiently expressed.
- administration method is not particularly limited, parenteral administration is preferred, and intravenous administration is more preferred.
- a medicament in the form of a pharmaceutical composition can be prepared with appropriate pharmaceutical additives and administered.
- nucleic acid When a nucleic acid is introduced into a nucleus of an immunocyte, preferably dendritic cell, by using the lipid membrane structure of the present invention, the encapsulated substance, i.e., the nucleic acid, is efficiently released in the nucleus to induce expression of a polypeptide encoded by the nucleic acid.
- the nucleic acid encoding a polypeptide is introduced into the nucleus of dendritic cell by using the lipid membrane structure of the present invention, the polypeptide transcribed and translated from the nucleic acid is presented on the surface of the dendritic cell, and the living host can acquire immunity against the polypeptide. Therefore, it becomes possible to perform effective immunotherapy against any desired polypeptide.
- This embodiment is a particularly preferred embodiment of the present invention.
- the lipid membrane structure provided by the present invention itself can exhibit an adjuvant action for dendritic cells and promote production of various cytokines. Therefore, by using the lipid membrane structure of the present invention, immunotherapy can be highly efficiently performed. Further, by administering dendritic cells transformed with the lipid membrane structure provided by the present invention to a mammal including human, exacerbation or proliferation of tumor can be remarkably suppressed irrespective of the presence or absence of adjuvant, and when the lipid membrane structure encapsulating an antigen protein is administered, cytotoxicity can be enhanced in viva Therefore, the lipid membrane structure can be used as a highly effective active ingredient of a vaccine for prophylactic treatment of malignant tumor or a medicament for therapeutic treatment of malignant tumor.
- a plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL.
- a 0.1 mg/mL solution of protamine 150 ⁇ L, 10 mM HEPES buffer
- was dropped portionwise with the pDNA solution 100 ⁇ L with stirring to prepare a compaction body of protamine and the pDNA (N/P ratio was 2.2).
- a 1 mM solution of DOPE (112.5 ⁇ L) and a 1 mM solution of CHEMS (25 ⁇ L) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2.
- the mixture was added with a 1 mg/mL solution of Chol-GALA synthesized according to the method described in Biochemistry, 43, pp. 5618-5628, 2004, and a 1 mg/mL solution of stearylated KALA (STR-KALA) synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No.
- a plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL. Polyrotaxane synthesized according to the method described in J. Control. Release, 131, pp.
- a 1 mM solution of DOPE (107 ⁇ L) and a 1 mM solution of phosphatidic acid (PA, 25 ⁇ L) were put into a glass test tube so as to obtain a DOPE:PA ratio of 7:2.
- the mixture was added with a 1 mg/mL solution of STR-KALA, synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857, in a volume for modifying 1.5 to 5% of the total lipids (8.25 to 27.5 ⁇ L), and further added with chloroform to a total volume of 200 ⁇ L, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane.
- STR-KALA synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857
- This lipid membrane was added with the compaction body prepared in the section (c) mentioned above so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and then ultrasonicated for 1 minute with a sonicator.
- the mixture was added with a 2 mg/mL aqueous solution of stearylated octaarginine (STR-R8) synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857 in such a volume that the added STR-R8 amount corresponded to 10 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes for hydration.
- STR-R8 stearylated octaarginine
- the JAWS II cells were inoculated on a 24-well plate at a density of 8 ⁇ 10 4 cells/well, and cultured for 24 hours in the ⁇ MEM medium. After the cultured cells were washed with 500 ⁇ L of PBS, the liposomes prepared in the sections (b) and (d) mentioned above, and control liposomes (not modified with stearylated KALA and Chol-GALA) were each added to ⁇ MEM so that a pDNA amount of 0.4 ⁇ g/well was to be obtained, the mixture was added to each well, and incubation was performed at 37° C. and 5% CO 2 for 3 hours.
- the cells were washed with 500 ⁇ L of PBS, then 1 mL of ⁇ MEM was added to each well, and incubation was further performed under the conditions of 37° C. and 5% CO 2 for 21 hours to prepare transformed cells.
- the transformed cells prepared in the section (e) mentioned above were washed with 500 ⁇ L of PBS, this PBS was collected into a 1.5-mL sample tube, and centrifuged (4° C., 2,000 rpm, 2 minutes), and the supernatant was removed. Each well was added with 75 ⁇ L of Reporter Lysis Buffer (Promega), and the plate was transferred to a freezer at ⁇ 80° C. to freeze the cell suspension. After the frozen sample was thawed, the cells were scraped off with a cell scraper, and collected in a 1.5-mL sample tube. A lysate of the collected cells was centrifuged (4° C., 15,000 rpm, 5 minutes), and 45 ⁇ L of the supernatant was collected.
- Reporter Lysis Buffer Promega
- the luciferase activity (RLU/mL) in the resulting supernatant was measured. Further, proteins were quantified (mg/mL) by the BCA method, the luciferase activity per unit amount of polypeptide (RLU/mg protein) was calculated, and the luciferase expression amounts were compared. Results are shown in FIG. 1 .
- a 3.3 mM solution of cardiolipin (CL, 84 ⁇ L) and a 10 mM solution of DOPE (27.5 ⁇ L) were put into a glass test tube so as to obtain a CL:DOPE ratio of 1:1.
- the mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 0.5%, 1%, 2%, or 5% of the total lipids, and further added with chloroform to a total volume of 200 ⁇ L, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained.
- This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect four kinds of liposomes (SUV1-1 to 5) of different STR-KALA concentrations.
- a 10 mM solution of PA (12.2 ⁇ L) and a 10 mM solution of DOPE (42.8 ⁇ L) were put into a glass test tube so as to obtain a PA:DOPE ratio of 7:2.
- the mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 1.5% of the total lipids, and further added with chloroform to a total volume of 200 ⁇ L, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained.
- This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect liposomes (SUV2).
- the compaction body (100 ⁇ L) obtained in Example 1, (c), and a solution of each of SUV1-1 to 5 (200 ⁇ l) were mixed in a 1.5-mL sample tube to form five kinds of bilamellar liposomes (D-MEND).
- D-MEND bilamellar liposomes
- a 2 mg/mL solution of STR-R8 was added to each kind of SUV1 liposomes in such a volume that the added STR-R8 amount corresponded to 20 mol % of the total lipid amount of SUV1, and the mixture was incubated at room temperature for about 30 minutes to attain modification with R8.
- each solution (200 ⁇ L) undergone the above incubation was added with 400 ⁇ L of SUV2, and then mixed in a 1.5-mL sample tube to form tetralamellar MEND (T-MEND). Further, T-MEND was added with a 2 mg/mL solution of STR-R8 so that the added STR-R8 amount corresponded to 10 mol % of the total lipid amount of SUV2, and the mixture was incubated at room temperature for about 30 minutes to prepare cationic T-MEND having KALA and R8 on both inner membrane and outer membrane.
- a plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL.
- the 0.1 mg/mL pDNA solution (60 ⁇ L) was dropped portionwise with a solution of polyrotaxane (1 mM in terms of amine concentration, 90 ⁇ L, average polyethylene glycol chain length: 4,000, number of threaded cyclodextrin: 29, average number of cations in one chain: 46) with stirring to prepare a compaction body of polyrotaxane and pDNA (N/P ratio was 0.5).
- a 3.3 mM solution of cardiolipin (CL, 84 ⁇ L) and a 10 mM solution of DOPE (27.5 ⁇ L) were put into a glass test tube so as to obtain a CL:DOPE ratio of 1:1.
- the mixture was added with a 2 mg/mL solution of STR-R8 in such a volume that the added STR-R8 amount corresponded to 20 mol % of the total lipid amount, and a 1 mg/mL solution of STR-KALA in such a volume that the added STR-KALA amount corresponded to 0 or 5 mol % of the total lipid amount, and further added with chloroform to a total volume of 200 ⁇ L, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained.
- This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect of liposomes (SUV1-0 and 1-5).
- a 10 mM solution of PA (12.2 ⁇ L) and a 10 mM solution of DOPE (42.8 ⁇ L) were put into a glass test tube so as to obtain a PA:DOPE ratio of 7:2.
- the mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 0 or 1.5% of the total lipids (0 or 8.3 ⁇ L), and further added with chloroform to a total volume of 200 ⁇ L, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby two kinds of lipid membranes were obtained.
- Each lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect liposomes (SUV2-0 and 2-1.5).
- D-MEND-0 and ⁇ 5 bilamellar liposomes
- a 2 mg/mL solution of STR-R8 was added to each kind of liposomes in such a volume that the added STR-R8 amount corresponded to 5 mol % of the total lipid amount of SUV1, and the mixture was incubated at room temperature for about 30 minutes.
- each solution (D-MEND-0 and ⁇ 5, 200 ⁇ L) undergone the above incubation was added with 400 ⁇ L of SUV2-0 or 2-1.5, and mixed in a 1.5-mL sample tube to form tetralamellar MEND (T-MEND).
- T-MEND was added with a 2 mg/mL solution of STR-R8 in such a volume that the added STR-R8 amount corresponded to 10 mol % of the total lipid amount of SUV2, and the mixture was incubated at room temperature for about 30 minutes to prepare anionic T-MEND having KALA and R8 on both inner membrane and outer membrane.
- Transformed cells were prepared by using the two kinds of T-MEND prepared in the sections (a) and (b) mentioned above according to the method described in Example 1, (e), and expression amount of luciferase in each type of cells was measured according to the method described in Example 1, (f).
- increase in expression of the encapsulated gene was observed in a KALA modification density-dependent manner ( FIG. 2 ).
- the modification of inner membrane and outer membrane with KALA provided 10 times or higher gene expression.
- the anionic T-MEND gave gene expression higher than that obtainable with Lipofectamine PLUS, which is a marketed gene transfer reagent.
- a plasmid DNA encoding the albumen antigen (ovalbumin) as an antigen was introduced into dendritic cells by using various vectors, and the dendritic cells were collected 24 hours after the transfection, and washed with the medium. Then, 1 ⁇ 10 4 cells/100 ⁇ L of the dendritic cells and 2 ⁇ 10 5 cells/100 ⁇ L of the B3Z (MHC-I) cells were inoculated on a 96-well plate, and co-cultivated for 16 hours.
- the cells were washed with PBS, added with CPRG buffer (100 ⁇ L, obtained by dissolving 5 mM CPRG (Roche Diagnostics), 0.125% NP-40 (Igepal CA-630, SIGMA) and 9 mM MgCl 2 in redistilled water, dividing the solution into aliquots in a volume of 1 mL each, and the storing the aliquots at ⁇ 20° C. under light shielding), and incubated at 37° C. for 4 hours. Then, absorbance of the culture was measured at 595 nm by using Benchmark Plus Microplate Spectrophotometer (Bio-Rad). The absorbance values were normalized with reference to the value obtained for the medium containing only untreated dendritic cells, which was taken as 1. Results are shown in FIG. 3 .
- each of a pDNA solution and a protamine solution was diluted to 0.1 mg/mL with a 10 mM HEPES buffer.
- lipid membrane As for lipid membrane, a 1 mM solution of DOPE (112.5 ⁇ L) and a 1 mM solution of CHEMS (25 ⁇ L) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2, the mixture was added with CHCl 3 to a total volume of 200 ⁇ L, and then the mixture was dried in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained.
- This lipid membrane was added with a solution of the compaction body so that the total lipid concentration became 0.55 mM, and added with only STR-R8 in an amount corresponding to 5 mol % of the total lipid amount in the case of R8-MEND, or STR-KALA and STR-R8 in an amount corresponding to 5 mol % of the total lipids in the case of R8/KALA-MEND, and the mixture was left standing at room temperature for 10 minute for hydration, and then ultrasonicated for 1 minute with a sonicator.
- the JAWS-II cells were inoculated on a 6-well plate at a density of 4 ⁇ 10 5 cells/well.
- the cells were washed with 500 ⁇ L of PBS( ⁇ ), then added with 1 mL of an MEND solution prepared by diluting MEND with ⁇ MEM (serum-free, antibiotic-free) to a concentration of 2 ⁇ g/mL (in terms of concentration of the plasmid DNA) cell, and left standing at 37° C. in a 5% CO 2 incubator.
- MEND solution prepared by diluting MEND with ⁇ MEM (serum-free, antibiotic-free) to a concentration of 2 ⁇ g/mL (in terms of concentration of the plasmid DNA) cell, and left standing at 37° C. in a 5% CO 2 incubator.
- TRIzol Reagent Invitrogen
- the cells were scraped off with a cell scraper, and collected in an Eppendorf tube.
- the cells were mixed for 1 minute on a vortex mixer and stored at ⁇ 80° C.
- For purifying mRNA each sample was thawed at room temperature, added with 200 ⁇ L of chloroform, and mixed for 15 seconds on a vortex mixer. The sample was incubated at room temperature for 3 minutes, and then centrifuged under an environment of 4° C. at 12,000 rpm for 15 minutes. The supernatant was transferred to another Eppendorf tube, and added with 500 ⁇ L of isopropanol, and the mixture was incubated at room temperature for 10 minutes. The mixture was centrifuged in an environment of 4° C.
- RNA amount was quantified on the basis of absorbance at 260 nm measured by using Nano Drop (Thermo Scientific).
- RNA for DNA microarray experiment was prepared by using Quick Amp Labeling Kit one-color (Agilent) according to the protocol attached to the kit.
- cDNA was synthesized from 500 ng of the total RNA by reverse transcription reaction.
- Cy3-CTP was prepared from the cDNA by in vitro transcription.
- the labeled cRNA was purified by using RNeasy Mini Kit.
- concentration and Cy3 uptake amount were calculated by using NanoDrop to determine the quality.
- Cy3 uptake efficiency of the purified labeled cRNA probe was calculated from cRNA concentration (ng/ ⁇ L) and uptake amount of Cy3 (pmol/ ⁇ L). The calculation method is shown below.
- Cy3 uptake amount (pmol/ ⁇ L) (OD 550 ⁇ 10* ⁇ 1000)/(150 mM ⁇ 1 cm ⁇ 1 )
- Hybridization of the labeled cRNA to a mouse oligo-DNA microarray (4 ⁇ 44K) was performed by using Gene Expression Hybridization Kit according to the protocol attached to the kit.
- the labeled cRNA was randomly digested and thereby fragmented, and a hybridization solution was prepared by using 1.65 ⁇ g of RNA.
- a sample was applied to a microarray slide, hybridization was performed at 65° C. and 17 hours, and then the slide was washed with Expression Wash Buffer containing 10% Triton X-102.
- the microarray slide was scanned by using Agilent DNA Microarray Scanner (Agilent Technologies). For the measurement of Cy3, a laser of 532 nm was used. The created TIFF image was read by using Feature Extraction Software, and information of the spots (gene profile) was saved in the form of text file. The resulting expression profile was imported into GeneSpringGX11, and analyzed.
- control spots including the spots for recognition of the four corners of array are also detected. Therefore these spots were eliminated.
- genes with low expression level might give fluctuation of expression levels even for the same samples, such genes were eliminated.
- Those genes providing a Raw value of 100 or higher for at least one sample among all the samples were extracted, which value is the absolute value of signal intensity. After the quality control described above was performed, analysis was advanced for the 21995 genes as the object.
- the genes relating to immunity were extracted, and gene expression amounts obtained with 118-MEND and R8/KALA-MEND were compared. The results of this comparison are shown with values of expression amounts of the genes normalized relative to that of untreated cells, which is taken as 1. As a result, it was recognized that the degree of increase in expression of immunity-related genes obtained with R8/KALA-MEND was higher than that obtained with R8-MEND, and the expression of many of the genes increased in a time-dependent manner. From these results, it was revealed that KALA modifying the MEND surface had an adjuvant effect on dendritic cells ( FIG. 4 ).
- a lipid thin membrane consisting of EPC/Chol/CHEMS (molar ratio: 70:20:10) was prepared in a glass test tube, added with OVA (5 mg/mL, 10 mM HB) so that the lipid concentration became 10 mM, and hydrated at room temperature for 15 minutes. After the hydration, the lipid membrane was mixed on a vortex mixer, transferred to a 15-mL conical tube, frozen and thawed 5 times.
- the lipid membrane was subjected to extrusion through a membrane filter of 400 nm, the supernatant was removed by ultracentrifugation (43,000 rpm, 4° C., 30 minutes), and then the pellet was gently rinsed with 200 ⁇ L of HBG, and suspended again in an appropriate volume of HBG. According to the procedure described in the following section, the OVA concentration and the lipid concentration were determined. Before use in the experiment, the liposomes were added with STR-R8 (10 mg/mL) or STR-KALA (10 mg/mL) in an amount corresponding to 7.5% of the lipid molar concentration, and the mixture was incubated at room temperature for 30 minutes or more to prepare R8-Lip and KALA-Lip.
- R8-Lip had a particle size of 189.5 nm, PDI of 0.095 and zeta potential of 47.8 mV, and KALA-Lip had a particle size of 188.4 nm, PDI of 0.317, and zeta potential of 33.7 mV.
- a liposome solution (254) or OVA for preparation of calibration curve diluted with sterilized water to a volume of 1 mL was added with a 0.15% solution of sodium deoxycholate (100 ⁇ L), and the mixture was incubated at room temperature for 10 minutes.
- the mixture was added with a 72% solution of trichloroacetic acid (100 ⁇ L), the mixture was centrifuged (3,500 rpm, 4° C., 20 to 30 minutes), and then the supernatant was removed.
- the resulting pellet was dissolved in a 0.5% SDS solution in 0.1 N NaOH (50 ⁇ L), the solution was added with the BCA assay reagent (1 mL), and quantification was performed according to the protocol.
- the lipid concentration was determined by using Phospholipid C-Test Wako (Wako Pure Chemical Industries).
- R8-Lip or KALA-Lip enclosing 50 ⁇ g of OVA was subcutaneously administered (26G needle) to C57BL/6 mice (female, 7 to 9 weeks old).
- target cells prepared by the following method were administered.
- the spleen was extracted from a naive mouse sacrificed by cervical vertebra dislocation, and the cells were loosened in 3 to 5 mL of the RPMI 1640 medium contained in a petri dish, collected by using a 2.5-mL syringe, then passed through a nylon mesh, and transferred to a 50-mL conical tube.
- the cells were centrifuged (1600 to 1700 rpm, 4° C., 5 minutes), then the supernatant was removed, and the cells were suspended in 1 mL of the ACK Lysing Buffer (Lonza, Walkersville, Md.), incubated at room temperature for 5 minutes, and thereby hemolyzed.
- the cell suspension was added with the RPMI 1640 medium (9 mL), then the mixture was centrifuged, and the cells were further washed with the medium (10 mL), then suspended in a volume of 20 mL, passed through a nylon mesh, and transferred to two of 50-mL conical tubes. The cells were counted, centrifuged, and then suspended again in the medium (10 7 cells/mL).
- the cell suspension in one of the tubes were added with OVA 257-264 peptide (1 mM, final concentration: 5 ⁇ M), and this cell suspension was incubated under the conditions of 37° C. and 5% CO 2 for 60 minutes.
- the cells were washed with medium (10 mL) and PBS (10 mL)
- the cells pulsed with the OVA 257-264 peptide were suspended in PBS containing 5 ⁇ M of CFSE (Molecular Probe, CFSE High )
- the cells not pulsed with the OVA 257-264 peptide were suspended in PBS containing 0.5 ⁇ M CFSE (CFES Low ), both at a density of 3 ⁇ 10 7 cells/mL, and those cells were incubated at 37° C. for 10 minutes.
- the cells were washed twice with the RPMI 1640 medium (10 mL) and twice with PBS (10 mL), and finally suspended in PBS (5 ⁇ 10 7 cells/mL).
- the same amounts of two kinds of the cells stained at different concentrations were mixed immediately before administration, and administered to the immunized mice from the caudal vein (1 ⁇ 10 7 cells/200 ⁇ L/mouse, 26G needle).
- the spleen was extracted, hemolyzed in the same manner as described above, then washed with the RPMI 1640 medium (10 mL) and PBS (10 mL), and suspended in the FACS buffer (5 mL).
- the prepared cell suspension was passed through a nylon mesh, and transferred to a FACS tube, and number of CFSE-positive cells was measured with a flow cytometer. There were analyzed 7,500 cells stained at a low concentration (CFSE Low ).
- the CTL activity was calculated by comparing the cell numbers of CFSE High and cFsE Low . Errors between experiments were corrected by using the CFSE High /CFSE Low ratio of the naive mice.
- Results are shown in FIG. 5 .
- the vertical axis represents the CTL activity in terms of percentage of killed cell among the cells served as the target of CTL (cells pulsed with the OVA 257-264 peptide).
- the cells used as the target (CFSE High ) presented the OVA peptide as MHC class I presentation, and accordingly, the cell-killing effect observed in this evaluation was provided by OVA-specific CTL.
- R8-Lip is a carrier capable of inducing specific MHC class I presentation and antitumor activity in vivo (Nakamura, T. et al., Mol. Ther., 16, pp. 1507-1514, 2008).
- marked improvement in the CTL activity was provided by modifying the liposome surfaces with KALA instead of R8.
- both R8-Lip and KALA-Lip were used without adjuvant, the CTL activity of KALA-Lip was comparable to the CTL activity obtainable by using R8-Lip carrying a CpG sequence-containing oligonucleotide, which is known as an adjuvant.
- plasmid DNAs were prepared: (1) a plasmid DNA containing CpG sequences in the backbone, and also having CpG sequences in a region from the start codon to the stop codon of the luciferase sequence as a marker gene (pcDNA3.1-Luc(+), 425 CpG sequences in total), (2) a plasmid DNA not containing any CpG sequence in both the backbone and the region from the start codon to the stop codon of the luciferase sequence (pCpGfree-Luc(0), 0 of CpG sequence in total), (3) a plasmid DNA containing CpG sequences in the backbone, but not containing any CpG sequence in the region from the start codon to the stop codon of the luciferase sequence (pcDNA3.1-Luc(0), 332 CpG sequences in total), and (4) a plasmid DNA not containing any CpG sequence in the backbone, but containing CpG sequences in
- the expression vector pcDNA3.1 purchased from Invitrogen was used. Further, for the construction of the expression plasmid DNAs comprising a backbone not containing any CpG sequence ((2) and (4) mentioned above), the expression vector pCpGfree-mcs purchased from Invitrogen was used.
- the DNA fragment containing the luciferase sequence including CpG sequences was obtained by digesting pGL3-basic vector of Promega with the restriction enzymes HindIII and XbaI. This fragment was introduced into the pcDNA3.1 vector at the HindIII/XbaI sites (pcDNA3.1-Luc(+)).
- the multi-cloning site of pCpGfree-mcs (BglII-KpnI-EcoO109I-NcoI-NheI) was treated with BglII/NheI, and a double-stranded DNA fragment having ends complementary to the cleavage sites of these restriction enzymes was inserted to create a new multi-cloning site (BglII-PvuII-NcoI-XbaI-NheI) (pCpGfree-NEWmcs, FIG. 6 ).
- a gene encoding luciferase not having CpG sequence obtained by treating pORF-Luc::Sh- ⁇ CpG (Invivogen) with NcoI/NheI was introduced into pCpGfree-NEWmcs at the NcoI/NheI sites (pCpGfree-Luc(+1)).
- the plasmid DNA prepared by this method had only one CpG sequence after the 12th codon counted from the codons of the luciferase gene ( FIG. 7 ).
- the residual CpG sequence was eliminated by excising a portion of sequence containing the stop codon and the CpG sequence from pCpGfree-Luc(+1) by a DraIII/NheI treatment, and inserting an oligonucleotide having ends complementary to the above restriction enzyme digestion sites, and including a mutation at the site of the CpG sequence.
- the EcoRI site existing immediately downstream of the stop codon was replaced with the EcoRV site (pCpGfree-Luc(0), FIG. 8 ).
- the plasmid DNA (3) was prepared by inserting the CpG-free luciferase gene excised from pCpGfree-Luc(0) prepared in the construction of the plasmid DNA (2) by BglII/EcoRV digestion into pcDNA3.1 at the BamHI/RV site (pcDNA3.1-Luc(0)).
- the plasmid DNA (4) was prepared by inserting the luciferase coding gene obtained from pcDNA3.1-Luc(+) prepared in the construction of the plasmid DNA (1) by PmeI/XbaI treatment into pCpGfree-NEWmcs at the PvuII/XbaI digestion site (pCpGfree-Luc (+)).
- the thighbones and the neck bones were extracted from C57BL/6 mice (6 to 8 weeks old) sacrificed by cervical vertebra dislocation, mildly disinfected with 70% ethanol, and then immersed into PBS. Both ends of the bones were cut, and the bone marrow cells were pushed out into the RPMI 1640 medium by using a 1-mL syringe containing the medium (26G needle).
- the cell suspension was passed through a 40- ⁇ m cell strainer (FALCON), and transferred to a 50-mL conical tube. The cell suspension was centrifuged (450 g, 4° C., 5 minutes), then the supernatant was removed, and the cells were dispersed by tapping.
- the cells were added with ACK Lysing Buffer (1 mL), and they were mixed and left standing at room temperature for 3 to 5 minutes.
- the cell suspension was added with the medium (10 mL), the mixture was centrifuged, the supernatant was removed, and the cells were further washed twice with the medium (10 mL).
- the cells were suspended in the medium (10 mL), added to a 10-cm cell culture dish (FALCON), and cultured under the conditions of 37° C. and 5% CO 2 for 4 hours or more. Only the floating cells were collected into a 50-mL conical tube by gentle pipetting, and centrifuged, the supernatant was removed, and then the cells were suspended in the medium (10 mL), and counted.
- the cells were suspended in the medium at a density of 1 ⁇ 10 6 cells/mL, and added with GM-CSF (final concentration: 10 ng/mL), the cell suspension was dispensed on a 24-well plate (Corning, N.Y.) in a volume of 1 mL/well, and the culture was performed under the conditions of 37° C. and 5% CO 2 for two days. After two days and four days, floating cells were removed to leave aggregates of the cells, and the culture was added with a fresh GM-CSF-containing RPMI 1640 medium (1 mL) Floating and weakly adhered cells on the day 6 to 8 from the start of the culture in the presence of GM-CSF were used for the experiment as immature dendritic cells. The purity was 85 to 90% as determined by evaluation using the CD11c antibody (PE Anti-mouse CD 11c, Clone: N418, BioLegend).
- Each of the various plasmid DNAs obtained in the section (a) mentioned above was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL.
- a 0.1 mg/mL protamine solution 150 ⁇ L, 10 mM HEPES buffer
- was dropped portionwise with the pDNA solution 100 ⁇ L to prepare a compaction body of protamine and the pDNA (N/P ratio was 2.2).
- a 1 mM solution of DOPE (112.5 ⁇ L) and a 1 mM solution of CHEMS (25 ⁇ L) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2.
- the mixture was added with a 1 mg/mL solution of stearylated KALA (STR-KALA) in a volume for modifying 5% of the total lipids, and further added with chloroform to a total volume of 200 ⁇ L, and the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane.
- STR-KALA stearylated KALA
- This lipid membrane was added with the compaction body so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and ultrasonicated for 1 minute with a sonicator.
- the mixture was further added with stearylated KALA (STR-KALA, 1 mg/mL aqueous solution) in such a volume that the added STR-KALA amount corresponded to 5 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes.
- STR-KALA stearylated KALA
- a 1 mM solution of DOPE (112.5 ⁇ L) and a 1 mM solution of CHEMS (25 ⁇ L) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2, the mixture was further added with chloroform to a total volume of 200 ⁇ L, and the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane.
- This lipid membrane was added with the compaction body so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and then ultrasonicated for 1 minute with a sonicator.
- the mixture was added with stearylated R8 (STR-R8, 2 mg/mL aqueous solution) in such a volume that the added STR-R8 amount corresponded to 5 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes.
- stearylated R8 STR-R8, 2 mg/mL aqueous solution
- BMDCs induced by the method described in the section (b) mentioned above were inoculated on a 24-well plate at a density of 4 ⁇ 10 5 cells/well.
- the prepared MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.4 ⁇ g/well, and the volume was adjusted to 500 ⁇ L.
- the MEND solution was applied to each well, and incubation was performed under an environment of 37° C. and 5% CO 2 . After 3 hours, RPMI 1640 (containing serum and antibiotic, 500 ⁇ L) was added to each well, and the luciferase activity was measured further 21 hours afterward.
- the floating cells were collected together with the medium, and centrifuged (4° C., 500 g, 5 minutes), and the supernatant was removed to collect only the cells.
- the cells remained in each well and the floating cells collected above were added with Reporter Lysis Buffer (1 ⁇ ), and the both were mixed, adjusted to a total volume of 75 ⁇ L, subjected to pipetting, and frozen at ⁇ 80° C.
- the sample frozen at ⁇ 80° C. was thawed, and the cells were scraped off with a cell scraper and collected in an Eppendorf tube. A lysate of the collected cells was centrifuged at 15,000 rpm and 4° C.
- the results are shown in FIG. 9 .
- the left graph shows the gene expression activities obtained in BMDCs with R8-MEND and KALA-MEND using (1) pcDNA3.1-Luc(+) and (4) pCpGfree-Luc(0) prepared in the section (a).
- pCpGfree-Luc(0) was used, high gene expression activity-promoting effect was observed with both R8-MEND and KALA-MEND.
- OVA antigen gene sequence containing no CpG sequence was designed (DNA sequence of 1161 bp shown in SEQ ID NO: 2 of Sequence Listing), and custom-made synthesis thereof was entrusted (TAKARA). This sequence was subcloned into pCpGfree-NEWmcs at one of the multi-cloning sites thereof, the NcoI/NheI site (pCp Gfree-OVA(0)).
- the dendritic cells isolated and differentiated by the method described in Example 6, (b) were inoculated on a 24-well plate at a density of 4 ⁇ 10 5 cells/well.
- KALA-MEND was prepared by using the CpG-free OVA expression plasmid DNA (pCpGfree-OVA(0)) according to the method described in Example 6, (c).
- MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.4 ⁇ g/well, and the volume was adjusted to 500 ⁇ L.
- the MEND solution was applied to each well, and the mixture was incubated under an environment of 37° C. and 5% CO 2 .
- RPMI 1640 (containing serum and antibiotic, 500 ⁇ L) was added to each well, and the cells were collected further 21 hours afterward.
- BMDCs were activated by using CpG oligonucleotide as an adjuvant
- incubation was conducted at a concentration of 1 ⁇ g/mL with BMDCs for 1 hour in RPMI 1640 (serum-free, antibiotic-free) before the transfection of KALA-MEND.
- BMDCs on which only CpG as an adjuvant of DC was acted (2) BMDCs in which luciferase as a non-antigen protein was expressed by using KALA-MEND, (3) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND, and (4) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND, and which were activated with CpG adjuvant were prepared at a density of 4 ⁇ 10 5 cells/40 ⁇ L in PBS, and the total volume of each was administered to C57BL/6 mice (female, 8 weeks old) at the planta pedis.
- Dendritic cells isolated and differentiated by the method described in Example 6, (b) were inoculated on a 24-well plate at a density of 4 ⁇ 10 5 cells/well.
- KALA-MEND was prepared by using the CpG-free OVA expression plasmid DNA (pCpGfree-OVA(0)) according to the method described in Example 6, (c).
- MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.8 ⁇ g/well, and the volume was adjusted to 500 ⁇ L.
- the MEND solution was applied to each well, and incubation was performed under an environment of 37° C. and 5% CO 2 .
- RPMI 1640 (containing serum and antibiotic, 500 ⁇ L) was added to each well, and the cells were collected further 21 hours afterward.
- the antigen (OVA)-expressing tumor cells (E.G7-OVA cells, 8 ⁇ 10 5 cells) were transplanted to C57BL/6 mice (female, 8-weeks old) at the left flank, and on the day 15 and the day 22 after the transplantation, (1) untreated BMDCs, (2) BMDCs in which luciferase as a non-antigen protein was expressed by using KALA-MEND, and (3) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND were each suspended in 40 ⁇ L of PBS so that 4 ⁇ 10 5 BMDCs were contained, and administered to the mice at the planta pedis.
- the lipid membrane structure provided by the present invention can efficiently migrate into nuclei of any types of cells such as immunocytes including dendritic cells, efficiently release an encapsulated substance such as nucleic acid in the nuclei to allow expression of a polypeptide encoded by such a nucleic acid, and further exhibit an efficient adjuvant effect. Therefore, the lipid membrane structure has a characteristic feature that it enables effective immunotherapy against an arbitrary polypeptide for which immunotherapy is desired.
Abstract
A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.
Description
- This application is a Continuation of U.S. patent application Ser. No. 13/641,812, which is a National Stage of International Application No. PCT/JP2011/059738, filed Apr. 20, 2011, which claims priority to Japanese Application No. 2010-097888, filed Apr. 21, 2010. The disclosures of each of U.S. patent application Ser. No. 13/641,812 and PCT/JP2011/059738 are expressly incorporated by reference herein in their entireties.
- The present invention relates to a lipid membrane structure having intranuclear migrating property. More specifically, the present invention relates to a lipid membrane structure such as liposome that can easily migrate into the nucleus of an immunocyte, especially the nucleus of dendritic cell.
- As a means for transporting a medicament specifically to a pathological lesion, methods of encapsulating a medicament in liposomes have been proposed. In particular, in the field of therapeutic treatments of malignant tumors, many reports have been made as for effectiveness of liposomes encapsulating an antitumor agent. Further, a multifunctional envelope-type nano device (MEND: henceforth sometimes abbreviated as “MEND” in the specification, see, for example, Drug Delivery System, 22-2, pp. 115-122, 2007 and the like) has been proposed. This structure can be used as a drug delivery system for delivering a gene or the like selectively into particular cells, and is known to be useful for, for example, gene therapy of tumors and the like.
- Variety of methods have been proposed for modifying the surface of a lipid membrane structure with a functional molecule, as means for delivering an objective substance such as medicaments, nucleic acids, peptides, polypeptides, and saccharides to specific parts such as target organs and tumor tissues using a lipid membrane structure. When a lipid membrane structure encapsulating a medicament such as antitumor agent reaches a target cell, the structure is taken up into the cell by endocytosis and enclosed in the endosome. Then, the structure releases the encapsulated medicament into the cytoplasm due to hydrolytic action of an enzyme in the lysosome or the like. In order to enhance the release of medicament from a liposome taken up into the endosome, a liposome has been proposed of which surface is modified with a peptide, GALA (Biochemistry, 26, pp. 2964-2972, 1987 for the peptide; Biochemistry, 43, pp. 5618-5623, 2004 for the liposome) and MEND (Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030).
- Further, as means for localization of a lipid membrane structure encapsulating an objective substance such as nucleic acid into the nucleus of a target cell, there have been proposed, for example, a liposome of which outer surface is modified with octaarginine (International Patent Publication WO2005/32593; Journal of Controlled Release, 98, pp. 317-323, 2004), a bilamellar liposome having a lipid membrane modified with a nucleus permeable peptide (International Patent Publication WO2006/101201), and a liposome of which surface is modified with a monosaccharide such as galactose and mannose (International Patent Publication WO2007/102481). It has been reported that a multilamellar lipid membrane structure (T-MEND) modified with a monosaccharide has fusability with a lipid membrane and a nuclear membrane, and is capable of improving gene expression efficiency as an experimental result in vitro.
- If a nucleic acid encoding an antigenic protein can be introduced into the nucleus of an immunocyte, especially dendritic cell having an antigen-presenting action, a protein transcribed and translated from the nucleic acid in the dendritic cell can be presented as an antigen on the surface of the dendritic cell, and the host organism can acquire immunity against that protein. From such point of view, a technique for efficiently delivering a nucleic acid into the nucleus of immunocyte, such as dendritic cell has been desired.
- However, where a nucleic acid is introduced into the nucleus of dendritic cell by using a lipid membrane structure such as the aforementioned MEND, the nucleic acid introduction efficiency is insufficient compared with introduction into other cells, for example, tumor cells and hepatic parenchymal cells. Before an introduced nucleic acid is finally expressed in the nucleus, the nucleic acid inevitably undergoes various intracellular kinetic processes such as uptake into cell, escape from endosome, migration into nucleus, and intranuclear transcription. However, in nondividing cells such as dendritic cell, an intact double-layered nuclear membrane constantly exist, and it is estimated that this nuclear membrane inhibits the intranuclear migrating ability of the lipid membrane structure. Therefore, in order to deliver a nucleic acid into the nucleus of dendritic cell by using a lipid membrane structure, it is a very important object how the nucleic acid successfully overcomes each of the aforementioned processes, especially, the barrier of the double-layered nuclear membrane.
- In addition, a polypeptide consisting of 27 amino acid residues called KALA peptide is known, and it has been reported that the peptide can form a complex with a plasmid DNA using cationic charge of itself (Biochemistry, 36, pp. 3008-3017, 1997). However, this reference fails to suggest whether or not this peptide promotes intranuclear migration of a lipid membrane structure.
-
- Patent document 1: International Patent Publication WO2005/32593
- Patent document 2: International Patent Publication WO2006/101201
- Patent document 3: International Patent Publication WO2007/102481
- Patent document 4: Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030
-
- Non-patent document 1: Drug Delivery System, 22-2, pp. 115-122, 2007
- Non-patent document 2: Biochemistry, 26, pp. 2964-2972, 1987
- Non-patent document 3: Biochemistry, 43, pp. 5618-5623, 2004
- Non-patent document 4: Journal of Controlled Release, 98, pp. 317-323, 2004
- Non-patent document 5: Biochemistry, 36, pp. 3008-3017, 1997
- An object of the present invention is to provide a means for efficiently delivering a nucleic acid into the nucleus of an immunocyte, especially dendritic cell having an antigen-presenting ability. More specifically, the object of the present invention is to provide a lipid membrane structure that can efficiently deliver a nucleic acid into the nucleus of an immunocyte such as dendritic cell.
- In order to achieve the aforementioned object, the inventors of the present invention attempted to introduce a nucleic acid enclosed in MEND modified with an octaarginine polypeptide as a functional polypeptide that can enhance nuclear migrating property (International Patent Publication WO2005/32593), or MEND modified with the GALA peptide as a functional polypeptide that imparts endosomal escaping ability (Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030) into dendritic cells, but almost no expression of a polypeptide from the nucleic acid was observed. Further, they also attempted to introduce a nucleic acid encapsulated in a multilamllar lipid membrane structure (T-MEND) comprising a lipid membrane having fusability with the endosome and a lipid membrane having fusability with the nuclear membrane into dendritic cells. However, presentation of a polypeptide expressed from the introduced nucleic acid on the surfaces of the dendritic cells was not observed, although promotion of the expression of the polypeptide was slightly observed in the nucleus.
- The inventors of the present invention further conducted researches, and as a result, found that when a lipid membrane of a lipid membrane structure such as MEND encapsulating a nucleic acid was modified with KALA peptide, efficiency of nucleic acid introduction into the nuclei of immunocytes such as dendritic cells was remarkably increased. The present invention was accomplished on the basis of the aforementioned finding.
- The present invention thus provides a lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with the following polypeptide (a) and/or polypeptide (b):
- (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1;
(b) a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1, which polypeptide has an activity of promoting migration of the lipid membrane structure into a nucleus of a cell. - According to preferred embodiments of the aforementioned lipid membrane structure, there are provided the aforementioned lipid membrane structure, wherein the lipid membrane structure is a liposome; the aforementioned lipid membrane structure, wherein the cell is an immunocyte, preferably dendritic cell; the aforementioned lipid membrane structure, wherein the polypeptides (a) and/or (b) are modified with a hydrophobic group, preferably stearyl group, cholesteryl group, or the like, and the hydrophobic group is inserted into the lipid membrane; the aforementioned lipid membrane structure, which has a polypeptide containing a plurality of contiguous arginine residues, preferably a polypeptide containing 4 to 20 contiguous arginine residues, more preferably a polypeptide consisting only of 4 to 20 contiguous arginine residues, most preferably octaarginine, on the surface thereof; the aforementioned lipid membrane structure, which has a polyalkylene glycol or a polyalkylene glycol, preferably a polyethylene glycol (PEG), condensed with a phospholipids, on the surface thereof; and the aforementioned lipid membrane structure, wherein ratio of cationic lipids to the total lipids constituting a lipid bilayer is 0 to 40% (molar ratio).
- Further, as another embodiment, there is provided any of the aforementioned lipid membrane structures, wherein a substance to be delivered is encapsulated in the inside of the lipid membrane structure. According to preferred embodiments of this invention, there are provided any of the aforementioned lipid membrane structures, wherein the substance to be delivered is a nucleic acid, for example, a functional nucleic acid such as a nucleic acid containing a gene or an siRNA; the aforementioned lipid membrane structure, wherein the substance to be delivered is DNA; the aforementioned lipid membrane structure, wherein the DNA is a DNA ligated with a vector DNA that does not contain CpG; the aforementioned lipid membrane structure, wherein the DNA does not contain CpG, and the DNA is a DNA ligated with a vector DNA that does not contain CpG; the aforementioned lipid membrane structure, wherein the substance to be delivered is a nucleic acid encoding an antigen polypeptide to be presented on the surface of an immunocyte, preferably surface of dendritic cell; any of the aforementioned lipid membrane structures, wherein the lipid membrane structure is a multifunctional envelope-type nano device (MEND); and any of the aforementioned lipid membrane structures, wherein a nucleic acid and a cationic polymer, preferably protamine, are encapsulated in the inside of the lipid membrane structure.
- There are also provided the aforementioned lipid membrane structure, which is used for introducing a nucleic acid encoding an antigen polypeptide to be presented on the surface of an immunocyte, preferably surface of dendritic cell, into a nucleus of the immunocyte; the aforementioned lipid membrane structure, which is for use in immunotherapy against the aforementioned antigen polypeptide; and the aforementioned lipid membrane structure, wherein the antigen polypeptide is a surface polypeptide specific to a cancer cell. The present invention also provides a pharmaceutical composition containing the above lipid membrane structure as an active ingredient, preferably a pharmaceutical composition containing a nucleic acid as a substance to be delivered.
- As other aspects of the present invention, there are provided a method for delivering a nucleic acid into a nucleus of a cell, preferably a nucleus of an immunocyte, more preferably a nucleus of dendritic cell, of a mammal including human in vivo, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating the nucleic acid inside thereof; and a method for presenting an antigen polypeptide on the surface of an immunocyte, preferably dendritic cell, in a mammal including human in vivo, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the antigen polypeptide inside thereof.
- There are also provided a method for presenting in vivo an antigen polypeptide on the surface of an immunocyte, preferably dendritic cell, in a mammal including human for immunization against the antigen polypeptide, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the antigen polypeptide inside thereof, and a method for immunotherapy of a malignant tumor by presenting in vivo a surface polypeptide specific to a cancer cell on the surface of an immunocyte, preferably dendritic cell, in a mammal including human for immunization against the polypeptide, which comprises the step of administering, to the mammal, the aforementioned lipid membrane structure encapsulating a nucleic acid encoding the polypeptide inside thereof.
- The present invention further provide a polypeptide used for promoting migration of a lipid membrane structure into a nucleus of a cell, preferably a nucleus of an immunocyte, more preferably a nucleus of dendritic cell, which consists of the following polypeptide (a) and/or polypeptide (b):
- (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1;
(b) a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1. - The lipid membrane structure provided by the present invention can efficiently migrate into a nucleus of an arbitrary cell, such as immunocytes including dendritic cell, and can effectively release an encapsulated substance such as nucleic acid in the nucleus to induce expression of a polypeptide encoded by the nucleic acid. Where a nucleic acid encoding a polypeptide is introduced into the nucleus of dendritic cell by using the lipid membrane structure of the present invention, the polypeptide transcribed and translated from the nucleic acid is presented on the surface of the dendritic cell, and the living host can acquire immunity against the polypeptide. Therefore, it becomes possible to perform effective immunotherapy against any desired polypeptides.
- Further, the lipid membrane structure provided by the present invention also has a characteristic feature that the lipid membrane structure itself can exhibit an adjuvant action for dendritic cells and promote production of various cytokines. Therefore, by administering dendritic cells transformed with the lipid membrane structure provided by the present invention, exacerbation or proliferation of tumor can be remarkably suppressed irrespective of the presence or absence of an adjuvant, and by administering the lipid membrane structure encapsulating an antigen protein, cytotoxicity can be enhanced in vivo. Furthermore, the lipid membrane structure also has a characteristic feature that, where CpG sequence is eliminated if desired from the vector moiety of DNA to be encapsulated, and also from DNA encoding a protein to be expressed, gene expression efficiency is markedly improved.
- [
FIG. 1 ] This figure depicts expression efficiency obtained with MEND of which lipid membrane was modified with the polypeptide (a) (KALA). - [
FIG. 2 ] This figure depicts gene expression efficiency obtained with tetralamellar cationic T-MEND and anionic T-MEND of which lipid membrane was modified with the polypeptide (a) (KALA). - [
FIG. 3 ] This figure depicts the results of presentation of antigen molecules on the surfaces of dendritic cells, which antigen molecules were expressed by introducing a gene encoding the antigen molecule into the nuclei of the dendritic cells using the lipid membrane structure of the present invention. - [
FIG. 4 ] This figure depicts the result that KALA modifying the surface of MEND has an adjuvant effect for dendritic cells. - [
FIG. 5 ] This figure depicts the CTL activity of protein-enclosing KALA-modified liposomes. - [
FIG. 6 ] This figure depicts a process of constructing a CpG-free plasmid DNA having a new multiple cloning site as the first step of the method for constructing the plasmid DNA (2) described in Example 6. - [
FIG. 7 ] This figure depicts a process of incorporating the luciferase gene into CpG-free NEWmcs as the second step of the method for constructing the plasmid DNA (2) described in Example 6. - [
FIG. 8 ] This figure depicts a process of removing the remained one CpG sequence as the third step of the method for constructing the plasmid DNA (2) described in Example 6. - [
FIG. 9 ] This figure depicts the gene expression activity-enhancing effect of KALA-MEND obtained by modification of vector of introduction plasmid. - [
FIG. 10 ] This figure depicts the result that MEND of which surface was modified with KALA showed high antitumor activity irrespective of the presence or absence of adjuvant. - [
FIG. 11 ] This figure depicts antitumor effect obtained by administering MEND of which surface was modified with KALA after the tumor was formed. - Examples of lipids constituting the lipid membrane structure of the present invention include, for example, phospholipids, glycolipids, sterols, saturated or unsaturated fatty acids, and the like.
- Examples of the phospholipids and phospholipid derivatives include, for example, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, cardiolipin, sphingomyelin, ceramide phosphorylethanolamine, ceramide phosphorylglycerol, ceramide phosphorylglycerol phosphate, 1,2-dimyristoyl-1,2-deoxyphosphatidylcholine, plasmalogen, phosphatidic acid, and the like, and one or more kinds of these can used independently or in combination. Although the fatty acid residues of these phospholipids are not particularly limited, examples include saturated or unsaturated aliphatic acid residues having 12 to 20 carbon atoms, and specific examples include, for example, acyl groups derived from such a fatty acid as lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, and linoleic acid. Further, a phospholipid derived from a natural product such as egg yolk lecithin and soybean lecithin can also be used.
- Examples of the glycolipids include glyceroglycolipids (for example, sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, and glycosyl diglyceride), sphingoglycolipids (for example, galactosyl cerebroside, lactosyl cerebroside and ganglioside), and the like.
- Examples of the sterols include animal-derived sterols (for example, cholesterol, cholesterol succinate, lanosterol, dihydrolanosterol, desmosterol and dihydrocholesterol), plant-derived sterols (phytosterol) (for example, stigmasterol, sitosterol, campesterol and brassicasterol), microorganism-derived sterols (for example, thymosterol and ergosterol), and the like.
- Examples of the saturated or unsaturated fatty acids include saturated or unsaturated fatty acids having 12 to 20 carbon atoms, such as palmitic acid, oleic acid, stearic acid, arachidonic acid, and myristic acid.
- Form of the lipid membrane structure is not particularly limited, and examples of the form in which lipid membrane structures are dispersed in an aqueous solvent include unilamella liposomes, multi-lamella liposomes, 0/W type emulsions, W/O/W type emulsions, spherical micelles, fibrous micelles, layered structures of irregular shapes and the like. Examples of preferred form of the lipid membrane structure of the present invention include liposomes. Although liposomes may be explained hereafter as a preferred embodiment of the lipid membrane structure of the present invention, the lipid membrane structure of the present invention is not limited to liposomes.
- The lipid membrane structure of the present invention is used for delivering a substance into a nucleus of a cell, and is characterized in that the lipid membrane is modified with the following polypeptide (a) and/or polypeptide (b): (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1; and (b) a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1, which polypeptide has an activity of promoting migration of the lipid membrane structure into a nucleus of a cell.
- The aforementioned polypeptide (a) represented by SEQ ID NO: 1 is a polypeptide consisting of 27 amino acid residues obtained by eliminating three amino acid residues from the C-terminus of the known polypeptide (WEAKLAKALAKALAKHLAKALAKALKACEA) consisting of 30 amino acid residues (henceforth this polypeptide may be called “KALA peptide” in this specification, Biochemistry, 36, pp. 3008-3017, 1997). Although this reference describes that the polypeptide can form a complex with a plasmid DNA using cationic charge of itself, the reference fails to describe whether or not this peptide promotes intranuclear migration of a lipid membrane structure. Further, the known KALA peptide comprises the sequence of the functional polypeptide consisting of 30 amino acid residues called GALA peptide (Bioor. Med. Chem., 5, pp. 1883-1891, 1997) including substitution of a plurality of amino acid residues with other amino acid residues (for example, a plurality of glutamine residues are replaced by lysine residues). However, the GALA peptide has a function of promoting fusion of lipid membranes in response to pH, and a function of enhancing ability of a lipid membrane structure to escape from the endosome, and these functions are different from the function of the KALA peptide used in the present invention (function of improving intranuclear migrating property of a lipid membrane structure in a cell).
- In the present invention, the polypeptide (b): a polypeptide consisting of an amino acid sequence including deletion and/or substitution and/or insertion of one or several amino acid residues in the amino acid sequence of SEQ ID NO: 1 (henceforth referred to as “modified polypeptide”), and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell may also be used. As the activity of promoting migration of the lipid membrane structure into the nucleus, for example, activity of promoting ability to migrate into the nucleus of dendritic cell can be evaluated. Where dendritic cell is as the target cell and the lipid membrane structures is used which encapsulates a nucleic acid inside thereof in a state that the nucleic acid can be expressed in the nucleus of the cell, for example, a nucleic acid encoding a polypeptide that is ligated downstream with a promoter operable in the nucleus of dendritic cell, the evaluation can be performed, for example, by preparing a lipid membrane structure wherein lipid membrane thereof is modified with the modified polypeptide (henceforth this lipid membrane structure is referred to as “modified lipid membrane structure”), and also by preparing a lipid membrane structure in which lipid membrane is not modified with the modified polypeptide (henceforth this lipid membrane structure is referred to as “unmodified lipid membrane structure”), and determining whether or not expression amount of the marker peptide in a cell introduced with the modified lipid membrane structure is increased compared with that of the marker peptide in a cell introduced with the unmodified lipid membrane structure. When an increase in the expression amount is observed, the modified polypeptide can be used as the aforementioned polypeptide (b). It is also possible to use one or more kinds of the aforementioned polypeptide (b) in combination with the polypeptide (a).
- The aforementioned polypeptide (a) and polypeptide (b) can be biologically prepared by using a host cell with various kinds of gene recombination techniques available to those skilled in the art. The aforementioned polypeptides may also be prepared by an organic chemical method utilizing a peptide synthesis reaction available for those skilled in the art, such as the solid phase synthesis method. Alternatively, they may also be automatically synthesized by using a peptide synthesizer.
- Although a means for fixing the aforementioned polypeptide (a) and/or polypeptide (b) to the lipid membrane of the lipid membrane structure is not particularly limited, the modification of the lipid membrane can be easily attained by, for example, modifying the aforementioned polypeptide (a) and/or polypeptide (b) with a hydrophobic group such as stearyl group or cholesteryl group, and preparing the lipid membrane structure so that the hydrophobic group is buried in the lipid membrane of the lipid membrane structure. As the hydrophobic group, a residue of arbitrary hydrophobic compound can be used. When a liposome having a multilamellar lipid membrane is used as the lipid membrane structure, the modification of lipid membrane with the aforementioned polypeptide (a) and/or polypeptide (b) may be performed for an inner lipid membrane as well as for an outer lipid membrane.
- The lipid membrane structure of the present invention can be used for delivering a substance into a nucleus of a cell. Type of the cell is not particularly limited, and an arbitrary cell can be used as the target depending on a type of the substance to be delivered, purpose of the delivery of substance into the nucleus, and the like. Preferred examples of the cell to be the target include immunocytes, and among immunocytes, antigen-presenting cells are preferably used. For example, antigen-presenting cells such as macrophage, dendritic cell, and B cell are preferred, and dendritic cell is particularly preferred.
- In order to promote permeation of the lipid membrane structure of the present invention into nuclei, surface of the lipid membrane structure can also be modified with, for example, a tri- or higher oligosaccharide compound. Although type of the tri- or higher oligosaccharide compound is not particularly limited, for example, an oligosaccharide compound comprising about 3 to 10 of linked saccharide units can be used, and an oligosaccharide compound comprising about 3 to 6 of linked saccharide units can be preferably used.
- More specifically, examples of the oligosaccharide compound include, for example, trisaccharide compounds such as cellotriose (β-D-glucopyranosyl-(1->4)-β-D-glucopyranosyl-(1->4)-D-glucose), chacotriose (α-L-rhamnopyranosyl-(1->2)-[α-L-rhamnopyranosyl-(1->4)]-D-glucose), gentianose (β-D-fructofuranosyl-β-D-glucopyranosyl-(1->6)-α-D-glucopyranoside), isomaltotriose (α-D-glucopyranosyl-(1->6)-α-D-glucopyranosyl-(1->6)-D-glucose), isopanose (α-D-glucopyranosyl-(1->4)-[α-D-glucopyranosyl-(1->6)]-D-glucose), maltotriose (α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucose), manninotriose (α-D-galactopyranosyl-(1->6)-α-D-galactopyranosyl-(1->6)-D-glucose), melezitose (α-D-glucopyranosyl-(1->3)-β-D-fructofuranosyl=α-D-glucopyranoside), panose (α-D-glucopyranosyl-(1->6)-α-D-glucopyranosyl-(1->4)-D-glucose), planteose (α-D-galactopyranosyl-(1->6)-β-D-fructofuranosyl=α-D-glucopyranoside), raffinose (β-D-fructofuranosyl=α-D-galactopyranosyl-(1->6)-α-D-glucopyranoside), solatriose (α-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->3)]-D-galactose), and umbelliferose (β-D-fructofuranosyl=α-D-galactopyranosyl-(1->2)-α-D-galactopyranoside; tetrasaccharide compounds such as lycotetraose (β-D-glucopyranosyl-(1->2)-[β-D-xylopyranosyl-(1->3)]-β-D-glucopyranosyl-(1->4)-β-D-galactose, maltotetraose (α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucose), and stachyose (β-D-fructofuranosyl=α-D-galactopyranosyl-(1->6)-α-D-galactopyranosyl-(1->6)-α-D-glucopyranoside); pentasaccharide compounds such as maltopentaose (α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucose, and verbascose (β-D-fructofuranosyl-α-D-galactopyranosyl-(1->6)-α-D-galactopyranosyl-(1->6)-α-D-galactopyranosyl-(1->6)-α-D-glucopyranoside; and hexasaccharide compounds such as maltohexaose (α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucose), but the oligosaccharide compound is not limited to these.
- Oligosaccharide compounds as trimer to hexamer of glucose can be preferably used, and oligosaccharide compounds as trimer or tetramer of glucose can be more preferably used. More specifically, isomalttriose, isopanose, maltotriose, maltotetraose, maltopentaose, maltohexaose, and the like can be preferably used, and among these, maltotriose, maltotetraose, maltopentaose, and maltohexaose consisting of glucose units linked through α1-4 linkages are more preferred. Particularly preferred are maltotriose and maltotetraose, and most preferred is maltotriose. Although amount of the oligosaccharide compound used for the surface modification of the lipid membrane structure is not particularly limited, it is, for example, about 1 to 30 mol %, preferably about 2 to 20 mol %, more preferably about 5 to 10 mol %, based on the total amount of lipids.
- Although the method for modifying the surface of the lipid membrane structure with the oligosaccharide compound is not particularly limited, for example, since liposomes consisting of lipid membrane structures of which surfaces are modified with monosaccharides such as galactose and mannose are known (International Patent Publication WO2007/102481), the surface modification method described in this publication can be employed. The entire disclosure of the aforementioned publication is incorporated into the disclosure of this specification by reference. This means is a method of binding a monosaccharide compound to polyalkylene glycolated lipids to perform surface modification of lipid membrane structures. Since surfaces of lipid membrane structures can be simultaneously modified with polyalkylene glycol by this means, it is preferred.
- Blood retainability of a liposome can be enhanced by modifying the surface of the lipid membrane structure as the liposome with a hydrophilic polymer such as polyalkylene glycol. This means is described in, for example, Japanese Patent Unexamined Publication (KOKAI) Nos. 1-249717, 2-149512, 4-346918, 2004-10481, and the like As the hydrophilic polymer, a polyalkylene glycol is preferred. As the polyalkylene glycol, for example, polyethylene glycol, polypropylene glycol, polytetramethylene glycol, polyhexamethylene glycol, and the like can be used. Molecular weight of the polyalkylene glycol is, for example, about 300 to 10,000, preferably about 500 to 10,000, more preferably about 1,000 to 5,000.
- The surface modification of the lipid membrane structure with a polyalkylene glycol can be easily performed by constructing the lipid membrane structure using, for example, a polyalkylene glycol-modified lipid as a lipid membrane-constituting lipid. For example, when the modification with a polyethylene glycol is performed, stearylated polyethylene glycols (for example, PEG45 stearate (STR-PEG45) and the like) can be used. In addition, polyethylene glycol derivatives, such as N-{carbonyl-methoxypolyethylene glycol 2000}-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, n-{carbonyl-methoxypolyethylene glycol 5000}-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, N-{carbonyl-methoxypolyethylene glycol 750}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, N-{carbonyl-methoxypolyethylene glycol 2000}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and N-{carbonyl-methoxypolyethylene glycol 5000}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, can also be used. However, the polyalkylene glycolated lipid is not limited to these.
- The surface modification of the lipid membrane structure can also be performed with, for example, the aforementioned polypeptide (a) and/or polypeptide (b) modified with a polyalkylene glycol. For example, the aforementioned polypeptide (a) and/or polypeptide (b) modified with a polyalkylene glycol condensed with an appropriate phospholipid, for example, a stearylated polyethylene glycol, can be used. For example, it is preferable to use a polypeptide in which a polyalkylene glycol is condensed to a cysteine (Cys) residue at the N- or C-terminus. In this embodiment, the modifications of the lipid membrane with a polyalkylene glycol and the aforementioned polypeptide (a), and/or polypeptide (b) can be simultaneously attained.
- Further, by binding an oligosaccharide compound to the polyethylene glycol, surface modification with a polyalkylene glycol and surface modification with an oligosaccharide compound can also be simultaneously attained. However, the method for modifying the surface of the lipid membrane structure with a polyalkylene glycol or an oligosaccharide compound is not limited to the aforementioned method. For example, the surface modification may be performed by using a lipidated compound such as a stearylated polyalkylene glycol or oligosaccharide compound as a constituent lipid of the lipid membrane structure.
- As lipid derivatives for enhancing retainability in blood used for the preparation of the lipid membrane structure of the present invention, for example, glycophorin, ganglioside GM1, phosphatidylinositol, ganglioside GM3, glucuronic acid derivative, glutamic acid derivative, polyglycerin-phospholipid derivative, and the like can be used. As hydrophilic polymer for enhancing retainability in blood, besides polyalkylene glycol, dextran, pullulan, Ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymer, divinyl ether-maleic anhydride alternating copolymer, amylose, amylopectin, chitosan, mannan, cyclodextrin, pectin, carrageenan, and the like can also be used for the surface modification.
- In order to efficiently extricate the lipid membrane structure from the inside of the endosome into the cytoplasm, the lipid membrane of the lipid membrane structure of the present invention may be modified with GALA. For example, since liposomes of which surfaces are modified with GALA are described in Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030, the lipid membrane structure of which surface is modified with GALA can be easily prepared according to the method described in the aforementioned publication. In general, by preparing a lipid membrane structure using a cholesterol derivative of GALA (Chol-GALA) as a lipid component, a lipid membrane structure of which surface is modified with GALA can be prepared. Although amount of GALA used for the surface modification of the lipid membrane structure is not particularly limited, it is, for example, about 0.01 to 10 mol %, preferably about 0.1 to 4 mol %, more preferably about 1 to 3 mol %, based on the total amount of lipids.
- The term “GALA” referred to in this specification include the peptide specified by SEQ ID NO: 1 mentioned in Sequence Listing of Japanese Patent Unexamined Publication (KOKAI) No. 2006.28030, as well as a modified peptide thereof having the amino acid sequence of the aforementioned peptide, but including deletion, substitution and/or addition of one or several amino acid residues, and having substantially the same properties as those of GALA (for example, a property that it can fuse lipid membranes under an acid condition). The term “GALA” used in this specification should not be construed in any limitative way. As for GALA and method for surface modification of a lipid membrane structure with GALA, the entire disclosure of Japanese Patent Unexamined Publication (KOKAI) No. 2006-28030 is incorporated into the disclosure of this specification by reference.
- Surface of the lipid membrane structure of the present invention may also be modified with an MPC polymer. The MPC polymer is an MPC polymer obtainable by polymerizing 2-methacryloyloxyethylphosphorylcholine (MPC). It has been demonstrated that, since this polymer has a molecular structure similar to that of biomembranes, it scarcely shows interactions with biological substances such as polypeptides and hemocytes, and shows superior biocompatibility. In this specification, the term “MPC polymer” is used for referring to both a homopolymer of MPC and a copolymer of MPC and another polymerization component.
- As the MPC polymer, commercial polymers can be easily obtained. For example, a homopolymer of MPC (CAS: 67881-99-6); a copolymer of MPC with butyl methacrylate (CAS: 125275-25-4); a terpolymer of MPC, sodium methacrylate and butyl methacrylate; a bipolymer of MPC and 2-hydroxy-3-(meth)acryloyloxypropyltrimethylammonium chloride; a phospholipid polymer (LIPIDURE-S), and the like are provided by NOF Corporation with the registered trademark of “LIPIDURE”, and any of these can be used for the present invention.
- Although type of the MPC polymer used for the present invention is not particularly limited, for example, a copolymer of MPC and a methacrylic acid ester such as butyl methacrylate, especially such a block copolymer, and the like can be preferably used. The preparation method of this copolymer is described in detail in Japanese Patent No. 2890316, and those skilled in the art can easily prepare a desired copolymer by referring to this patent publication. The entire disclosure of this patent publication is incorporated into the disclosure of this specification by reference. In the present invention, an MPC polymer showing water solubility and having a hydrophobic group is preferably used. From this point of view, an MPC copolymer prepared by using an acrylic acid ester or methacrylic acid ester having about 4 to 18 carbon atoms can be preferably used. As a copolymer of MPC and butyl methacrylate (BMA), for example, a copolymer having a molar ratio of MPC and BMA of 5:5 (PMB50), a copolymer having a molar ratio of MPC and BMA of 3:7 (PMB30), and the like are known, and it can be easily prepared according to, for example, the method described in Polymer Journal, 22, pp. 355-360, 1990, or the like (specific preparation methods are explained in, for example, Japanese Patent Unexamined Publication (KOKAI) No. 2007-314526). For the present invention, PMB50 can be most preferably used. Although degree of polymerization and molecular weight of the MPC polymer are not particularly limited, a polymer having an average molecular weight (weight average molecular weight) of, for example, about 5,000 to 300,000, preferably about 10,000 to 100,000, can be used from a viewpoint of maintaining water solubility.
- Although the method for modifying the lipid membrane structure with the MPC polymer is not particularly limited, for example, an MPC polymer can be added to an aqueous dispersion of the lipid membrane structure such as liposomes, and the mixture can be left at room temperature for about several minutes to several hours. Although amount of the MPC polymer to be added to the aforementioned aqueous dispersion is not particularly limited, it may be added in an amount corresponding to the amount of the MPC polymer used for the modification, for example, 0.01 to 1 mass %, preferably about 0.1 to 10 mass %, more preferably about 0.1 to 3 mass %, based on the total amount of lipids of the lipid membrane structure. By this operation, the MPC polymer is quickly taken up into the lipid components of the lipid membrane structure, and the lipid membrane structure of which surface is modified with the MPC polymer can be prepared. Although amount of the MPC polymer used for the surface modification is not particularly limited, it is, for example, in the range of about 0.1 to 5 mass % based on the total amount of lipids of the lipid membrane structure.
- The lipid membrane structure of the present invention may contain one or two or more kinds of substances selected from the group consisting of a membrane stabilization agent such as sterol, glycerol, and a fatty acid ester thereof, an antioxidant such as tocopherol, propyl gallate, ascorbyl palmitate, and butylated hydroxytoluene, a chargeable substance, a membrane polypeptide, and the like. Examples of the chargeable substance that imparts positive charge include saturated or unsaturated fatty amines such as stearylamine and oleylamine; saturated or unsaturated synthetic cationic lipids such as dioleoyltrimethylammonium propane; cationic polymers, and the like, and examples of the chargeable substance that imparts negative charge include, for example, dicetyl phosphate, cholesteryl hemisuccinate, phosphatidylserine, phosphatidylinositol, phosphatidic acid, and the like. Examples of the membrane polypeptide include, for example, extrinsic membrane polypeptides, integral membrane polypeptides, and the like. Amounts of these substances to be added are not particularly limited, and can be appropriately chosen depending on the purpose.
- Further, the lipid membrane structure of the present invention may be imparted with one or two or more functions selected from, for example, temperature change sensing function, membrane permeating function, gene expressing function, pH sensing function, and the like. By appropriately imparting these functions, retainability in blood of the lipid membrane structure encapsulating, for example, a nucleic acid containing a gene or the like can be improved, a rate of capture by reticuloendothelial systems of liver, spleen and the like can be reduced, the lipid membrane structure can be efficiently extricated from the endosome and transferred to the nucleus after endocytosis of a target cell, and it becomes possible to attain high gene expression activity in the nucleus.
- Examples of temperature change-sensitive lipid derivatives that can impart the temperature change sensing function include, for example, dipalmitoylphosphatidylcholine and the like. Examples of pH-sensitive lipid derivatives that can impart the pH sensing function include, for example, dioleoylphosphatidylethanolamine and the like.
- Further, the lipid membrane structure of the present invention may also be modified with a substance that can specifically bind with a receptor or antigen on the surface of a cell, such as antibodies, to improve efficiency of delivery of a substance into the nucleus. For example, a monoclonal antibody directed to a biological component specifically expressed in a target tissue or organ is preferably disposed on the surface of the lipid membrane structure. This technique is described in, for example, STEALTH LIPOSOME (pages 233 to 244, published by CRC Press, Inc., edited by Danilo Lasic and Frank Martin) and the like As a component of the lipid membrane structure, there can be contained a lipid derivative that can react with mercapto group in a monoclonal antibody or a fragment thereof (e.g., Fab fragment, F(ab′)2 fragment, Fab′ fragment and the like), specifically, a lipid derivative having a maleinimide structure such as poly(ethylene glycol)-α-distearoylphosphatidylethanolamine-ω-maleinimide and α-[N-(1,2-distearoyl-sn-glycero-3-phosphorylethyl)carbamyl]-ω-{3-[2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)ethanecarboxamido]propyl}-poly(oxy-1,2-ethanediyl), and thereby the monoclonal antibody can be bound to the surface of the membrane of the lipid membrane structure.
- Surface of the lipid membrane structure of the present invention may be modified with a polypeptide containing a plurality of contiguous arginine residues (henceforth referred to as “polyarginine”). As the polyarginine, preferably a polypeptide containing 4 to 20 contiguous arginine residues, more preferably a polypeptide consisting only of 4 to 20 contiguous arginine residues, most preferably octaarginine, and the like can be used. By modifying the surface of a lipid membrane structure such as liposome with a polyarginine such as octaarginine, intracellular delivery efficiency of a target substance enclosed in liposome can be improved (Journal of Controlled Release, 98, pp. 317-323, 2004; International Patent Publication WO2005/32593). Surface of the lipid membrane structure can be easily modified with a polyarginine according to the method described in the aforementioned publications using, for example, a lipid-modified polyarginine such as stearylated octaarginine as a constituent lipid of the lipid membrane structure. The disclosures of the aforementioned publications and the disclosures of all of the references cited in the publications are incorporated into the disclosure of this specification by reference.
- Furthermore, surface of the lipid membrane structure of the present invention may be modified with INF7. INF7 is a glutamic acid-rich peptide obtained by modifying a peptide (1-23) derived from the influenza HA polypeptide (HA2), and it has been reported that the lipid structure of liposomes is collapsed in the presence of INF7, and a substance enclosed in the liposomes is easily released (Biochemistry, 46, pp. 13490-13504, 2007). There has also been proposed a delivery system comprising polyethylene glycol tetraacrylate (PEG-TA) bound with INF7 (The Journal of Gene Medicine, 10, pp. 1134-1149, 2008). Those skilled in the art can easily use INF7 in the present invention by referring to these publications. The term “INF7” used in this specification is used to refer to the peptide specified by the sequence described in Biochemistry, 46, pp. 13490-13504, 2007, Table 1, as well as a modified peptide thereof having the amino acid sequence of the aforementioned peptide, but including deletion, substitution and/or addition of one or several amino acid residues, and having substantially the same properties as those of INF7. The term “INF7” used in this specification should not be construed in any limitative way. The disclosures of the aforementioned publications and the disclosures of all of the references cited in these publications are incorporated into the disclosure of this specification by reference.
- Although the method for modifying the lipid membrane structure with INF7 is not particularly limited, the lipid membrane structure of which surface is modified with INF7 can generally be easily prepared by constructing the lipid membrane structure by using a lipid-modified INF7 comprising a lipid compound and INF7 covalently bound with each other as a lipid membrane constituent lipid. As the lipid-modified INF, for example, stearylated INF7 and the like can be used. This compound can be easily prepared according to the method described in Futaki, S. et al., Bioconjug. Chem., 12 (6), pp. 1005-1011, 2001. Although amount of INF7 used for the surface modification is not particularly limited, it is generally in the range of 1 to 5 mole %, preferably about 3 to 5 mole %, based on the total amount of lipids of the lipid membrane structure.
- A multifunctional envelope-type nano device (MEND) is known, and it can be preferably used as the lipid membrane structure of the present invention. MEND has, for example, a structure that it contains a complex of a nucleic acid such as plasmid DNA and a cationic polymer such as protamine as a core, and the core is enclosed in the inside of a lipid envelope membrane in the form of liposome. On the lipid envelope membrane of MEND, a peptide for adjusting pH responding property and membrane permeability can be disposed as required, and the external surface of the lipid envelope membrane can be modified with an alkylene glycol such as polyethylene glycol. Condensed DNA and the cationic polymer are enclosed in the inside of the lipid envelope of MEND, and it is designed so that gene expression can be efficiently attained. As MEND suitably used for the present invention, MEND in which a complex of a plasmid DNA incorporated with a desired gene and protamine is enclosed in the inside, and the outer surface of the lipid envelope is modified with an oligosaccharide-bound PEG is preferred. For the modification with the oligosaccharide-bound PEG, it is preferable to use stearylated polyethylene glycol bound with the polypeptide (a) and/or the polypeptide (b) mentioned above as a constituent lipid component. As for MEND, for example, references for general remarks, such as Drug Delivery System, 22-2, pp. 115-122, 2007, can be referred to. The disclosure of the aforementioned publication and the disclosures of all of the references cited in this publication are incorporated into the disclosure of this specification by reference.
- Although form of the lipid membrane structure is not particularly limited, examples include, for example, a dispersion in an aqueous solvent (for example, water, physiological saline, phosphate buffered physiological saline, and the like), a lyophilized product of the aqueous dispersion, and the like.
- The method for preparing the lipid membrane structure is not particularly limited, either, and an arbitrary method available for those skilled in the art can be employed. For example, the lipid membrane structure can be prepared by dissolving all the lipid components in an organic solvent such as chloroform, forming a lipid membrane by exsiccation under reduced pressure in an evaporator or spray drying using a spray dryer, then adding an aqueous solvent to the aforementioned dried mixture, and emulsifying the mixture with an emulsifier such as homogenizer, an ultrasonic emulsifier, a high pressure injection emulsifier, or the like. Further, it can be prepared by a method well known as a method for preparing liposomes, for example, the reverse phase evaporation method, and the like. When it is desired to control the size of the lipid membrane structure, extrusion (extrusion filtration) can be performed under high pressure by using a membrane filter having pores of uniform diameters, or the like. Although size of the dispersed lipid membrane structure is not particularly limited, in the case of liposome, for example, particle size is about 50 nm to 5 μm, preferably about 50 nm to 400 nm, more preferably 50 nm to 300 nm, still more preferably 150 nm to 250 nm. The particle size can be measured by, for example, the DLS (dynamic light scattering) method.
- The composition of the aqueous solvent (dispersion medium) is not particularly limited, and examples include, for example, a buffer such as phosphate buffer, citrate buffer, and phosphate-buffered physiological saline, physiological saline, a medium for cell culture and the like. Although the lipid membrane structure can be stably dispersed in these aqueous solvents (dispersion media), the solvents may be further added with a saccharide (aqueous solution), for example, a monosaccharide such as glucose, galactose, mannose, fructose, inositol, ribose and xylose, a disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose, a trisaccharide such as raffinose and melezitose, and polysaccharide such as cyclodextrin, a sugar alcohol such as erythritol, xylitol, sorbitol, mannitol, and maltitol, or a polyhydric alcohol (aqueous solution) such as glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol mono-alkyl ether, diethylene glycol monoalkyl ether and 1,3-butylene grycol. In order to stably store the lipid membrane structure dispersed in such an aqueous solvent for a long period of time, it is desirable to minimize electrolytes in the aqueous solvent from a viewpoint of physical stability such as prevention of aggregation. Further, from a viewpoint of chemical stability of lipids, it is desirable to control pH of the aqueous solvent to be in a range of from weakly acidic pH to around neutral pH (around pH 3.0 to 8.0), and/or to remove dissolved oxygen by nitrogen bubbling or the like.
- When the resulting aqueous dispersion of the lipid membrane structure is lyophilized or spray-dried, use of a saccharide (aqueous solution), for example, a monosaccharide such as glucose, galactose, mannose, fructose, inositol, ribose and xylose, a disaccharide such as lactose, sucrose, cellobiose, trehalose and maltose, a trisaccharide such as raffinose and melezitose, a polysaccharide such as cyclodextrin, a sugar alcohol such as erythritol, xylitol, sorbitol, mannitol, and maltitol or the like may improve stability. When the aforementioned aqueous dispersion is frozen, use of the aforementioned saccharide or a polyhydric alcohol (aqueous solution) such as glycerin, diglycerin, polyglycerin, propylene glycol, polypropylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, ethylene glycol mono-alkyl ether, diethylene glycol mono-alkyl ether and 1,3-butylene glycol may improve stability.
- In the inside of the lipid membrane structure of the present invention, for example, liposome, a substance to be delivered to the inside of a nucleus of a cell in a target tissue or organ can be enclosed. Although type of the substance to be enclosed is not particularly limited, active ingredients of arbitrary medicaments such as antitumor agent, anti-inflammatory agent, antimicrobial agent, and antiviral agent as well as other arbitrary substances such as saccharides, peptides, nucleic acids, low molecular weight compounds, and metallic compounds can be enclosed. Examples of the nucleic acid include a nucleic acid containing a gene, and specific examples include, for example, a gene incorporated into a plasmid. However, the nucleic acid is not limited to these specific examples. Further, it is of course that arbitrary genes can be used as the gene. Although a case of enclosing a nucleic acid will be specifically explained below as an example of the present invention, the scope of the present invention is not limited to this specific embodiment.
- In the lipid membrane structure of the present invention, a nucleic acid can be preferably enclosed. The nucleic acid includes DNA and RNA, as well as analogues and derivatives thereof (for example, peptide nucleic acid (PNA), phosphorothioate DNA, and the like). The nucleic acid may be a single-stranded or double-stranded nucleic acid, and may be a linear or cyclic nucleic acid. The nucleic acid may contain a gene. The gene may be any of oligonucleotide, DNA, and RNA, and in particular, genes for in vitro induction such as transformation, genes acting after in vivo expression thereof, for example, genes for gene therapies such as normal genes for homologous recombination, and the like can be mentioned. As the nucleic acid for therapeutic treatment, antisense oligonucleotide, antisense DNA, antisense RNA, and a gene encoding an enzyme or a physiologically active substance such as cytokine, as well as a nucleic acid having a function of controlling gene expression, for example, a functional nucleic acid including RNA such as siRNA can also be used, and these are also encompassed within the scope of the term “nucleic acid” used in this specification. The term “nucleic acid” used in this specification must be construed in its broadest sense, and it should not be construed in any limitative way. For example, when a DNA is used as the nucleic acid, for example, a gene DNA to be expressed can be ligated to a vector DNA, and encapsulated in the lipid membrane structure. However, in order to attain further higher gene expression efficiency, it is preferred that the vector DNA does not contain any CpG sequence, and it may be more preferred that, in addition to the above, the gene DNA to be expressed does not contain any CpG sequence. It is preferred that an enhancer and/or a promoter is ligated to the vector.
- Further, when a nucleic acid is enclosed in the lipid membrane structure of the present invention, a compound having a nucleic acid-introducing function can also be added. Examples of such a compound include, for example, O,O′—N-didodecanoly-N-(α-trimethylammonioacetyl)-diethanolamine chloride, O,O′—N-ditetradecanoly-N-(α-trimethylammonioacetyl)-diethanolamine chloride, O,O′—N-dihexadecanoly-N-(α-trimethylammonioacetyli-diethanolamine chloride, O,O′—N-dioctadecenoyl-N-(α-trimethylammonioacetyli-diethanolamine chloride, O,O′,O″-tridecanoly-N-(ω-trimethylammoniodecanoyl)aminomethane bromide, N-[α-trimethylammonioacetyl]-didodecyl-D-glutamate, dimethyldioctadecylammonium bromide, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propane ammonium trifluoroacetate, 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide, 3-β-[N—(N′,N′-dimethylaminoethane)carbamoyl]cholesterol, and the like. These compounds having a nucleic acid-introducing function may be disposed at an arbitrary position of the membrane of the lipid membrane structure, and/or filled in the inside of the lipid membrane structure.
- For example, the lipid membrane structure encapsulating a nucleic acid can be used as a carrier for delivering the nucleic acid into a nucleus of a cell of a target tissue or organ. When aiming at gene expression, it is particularly preferable to use a nucleic acid containing a desired gene as the nucleic acid and the aforementioned MEND. For example, by administering a lipid membrane structure, preferably MEND, enclosing a nucleic acid containing a gene to a mammal including human, a desired gene can be delivered into nuclei of cells of a target tissue or organ, and efficiently expressed. Although administration method is not particularly limited, parenteral administration is preferred, and intravenous administration is more preferred. When the lipid membrane structure of the present invention is used as a medicament, for example, a medicament in the form of a pharmaceutical composition can be prepared with appropriate pharmaceutical additives and administered.
- When a nucleic acid is introduced into a nucleus of an immunocyte, preferably dendritic cell, by using the lipid membrane structure of the present invention, the encapsulated substance, i.e., the nucleic acid, is efficiently released in the nucleus to induce expression of a polypeptide encoded by the nucleic acid. Where a nucleic acid encoding a polypeptide is introduced into the nucleus of dendritic cell by using the lipid membrane structure of the present invention, the polypeptide transcribed and translated from the nucleic acid is presented on the surface of the dendritic cell, and the living host can acquire immunity against the polypeptide. Therefore, it becomes possible to perform effective immunotherapy against any desired polypeptide. This embodiment is a particularly preferred embodiment of the present invention.
- Further, the lipid membrane structure provided by the present invention itself can exhibit an adjuvant action for dendritic cells and promote production of various cytokines. Therefore, by using the lipid membrane structure of the present invention, immunotherapy can be highly efficiently performed. Further, by administering dendritic cells transformed with the lipid membrane structure provided by the present invention to a mammal including human, exacerbation or proliferation of tumor can be remarkably suppressed irrespective of the presence or absence of adjuvant, and when the lipid membrane structure encapsulating an antigen protein is administered, cytotoxicity can be enhanced in viva Therefore, the lipid membrane structure can be used as a highly effective active ingredient of a vaccine for prophylactic treatment of malignant tumor or a medicament for therapeutic treatment of malignant tumor.
- Hereafter, the present invention will be more specifically explained with reference to examples. However, the scope of the present invention is not limited to the following examples.
- A plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL. A 0.1 mg/mL solution of protamine (150 μL, 10 mM HEPES buffer) was dropped portionwise with the pDNA solution (100 μL) with stirring to prepare a compaction body of protamine and the pDNA (N/P ratio was 2.2).
- A 1 mM solution of DOPE (112.5 μL) and a 1 mM solution of CHEMS (25 μL) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2. The mixture was added with a 1 mg/mL solution of Chol-GALA synthesized according to the method described in Biochemistry, 43, pp. 5618-5628, 2004, and a 1 mg/mL solution of stearylated KALA (STR-KALA) synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857 in volumes for modifying 1 to 8% of the total lipids, and further added with chloroform to a total volume of 200 μL, and the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane. This lipid membrane was added with the compaction body prepared in the section (a) mentioned above so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and then ultrasonicated for 1 minute with a sonicator. The mixture was added with stearylated octaarginine (STR-R8) synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857 (2 mg/mL aqueous solution) in such a volume that the added STR-R8 amount corresponded to 5 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes.
- A plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL. Polyrotaxane synthesized according to the method described in J. Control. Release, 131, pp. 137-144, 2008 (average polyethylene glycol chain length: 4,000, number of threaded cydodextrin: 29, average number of cations in one chain: 46) was dissolved in a 10 mM HEPES buffer (1 mM in terms of amine concentration), and the resulting solution (150 μL) was dropped portionwise with the pDNA solution (100 μL) with stirring to prepare a compaction body of polyrotaxane and pDNA (N/P ratio was 5.0).
- A 1 mM solution of DOPE (107 μL) and a 1 mM solution of phosphatidic acid (PA, 25 μL) were put into a glass test tube so as to obtain a DOPE:PA ratio of 7:2. The mixture was added with a 1 mg/mL solution of STR-KALA, synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857, in a volume for modifying 1.5 to 5% of the total lipids (8.25 to 27.5 μL), and further added with chloroform to a total volume of 200 μL, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane. This lipid membrane was added with the compaction body prepared in the section (c) mentioned above so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and then ultrasonicated for 1 minute with a sonicator. The mixture was added with a 2 mg/mL aqueous solution of stearylated octaarginine (STR-R8) synthesized according to the method described in Japanese Patent Unexamined Publication (KOKAI) No. 2003-343857 in such a volume that the added STR-R8 amount corresponded to 10 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes for hydration.
- The JAWS II cells were inoculated on a 24-well plate at a density of 8×104 cells/well, and cultured for 24 hours in the αMEM medium. After the cultured cells were washed with 500 μL of PBS, the liposomes prepared in the sections (b) and (d) mentioned above, and control liposomes (not modified with stearylated KALA and Chol-GALA) were each added to αMEM so that a pDNA amount of 0.4 μg/well was to be obtained, the mixture was added to each well, and incubation was performed at 37° C. and 5% CO2 for 3 hours. After the incubation, the cells were washed with 500 μL of PBS, then 1 mL of αMEM was added to each well, and incubation was further performed under the conditions of 37° C. and 5% CO2 for 21 hours to prepare transformed cells.
- The transformed cells prepared in the section (e) mentioned above were washed with 500 μL of PBS, this PBS was collected into a 1.5-mL sample tube, and centrifuged (4° C., 2,000 rpm, 2 minutes), and the supernatant was removed. Each well was added with 75 μL of Reporter Lysis Buffer (Promega), and the plate was transferred to a freezer at −80° C. to freeze the cell suspension. After the frozen sample was thawed, the cells were scraped off with a cell scraper, and collected in a 1.5-mL sample tube. A lysate of the collected cells was centrifuged (4° C., 15,000 rpm, 5 minutes), and 45 μL of the supernatant was collected. The luciferase activity (RLU/mL) in the resulting supernatant was measured. Further, proteins were quantified (mg/mL) by the BCA method, the luciferase activity per unit amount of polypeptide (RLU/mg protein) was calculated, and the luciferase expression amounts were compared. Results are shown in
FIG. 1 . - As shown in
FIG. 1 , in the case of the liposomes encapsulating the core formed by using protamine with DOPE/CHEMS, when such liposomes modified with Chol-GALA were used, the gene expression was maximized at a modification amount of 2%, but increase of the gene expression was only about 3 times. Whilst when the liposomes modified with STR-KALA were used, it was found that the gene expression increased 10 times or more, and especially at a modification amount of 5%, the gene expression increased 100 times or more. Further, also in the case of the liposomes encapsulating the core formed by using polyrotaxane with lipids of DOPE/PA, when such liposomes modified in a similar manner were used, increase in the gene expression of 10 times or more was observed at the optimal modification amount of 1.5%, compared with the gene expression obtained with those modified only with R8. - A 3.3 mM solution of cardiolipin (CL, 84 μL) and a 10 mM solution of DOPE (27.5 μL) were put into a glass test tube so as to obtain a CL:DOPE ratio of 1:1. The mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 0.5%, 1%, 2%, or 5% of the total lipids, and further added with chloroform to a total volume of 200 μL, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained. This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect four kinds of liposomes (SUV1-1 to 5) of different STR-KALA concentrations.
- A 10 mM solution of PA (12.2 μL) and a 10 mM solution of DOPE (42.8 μL) were put into a glass test tube so as to obtain a PA:DOPE ratio of 7:2. The mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 1.5% of the total lipids, and further added with chloroform to a total volume of 200 μL, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained. This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect liposomes (SUV2).
- The compaction body (100 μL) obtained in Example 1, (c), and a solution of each of SUV1-1 to 5 (200 μl) were mixed in a 1.5-mL sample tube to form five kinds of bilamellar liposomes (D-MEND). After the formation of D-MEND, in order to apply positive charge, a 2 mg/mL solution of STR-R8 was added to each kind of SUV1 liposomes in such a volume that the added STR-R8 amount corresponded to 20 mol % of the total lipid amount of SUV1, and the mixture was incubated at room temperature for about 30 minutes to attain modification with R8.
- Further, each solution (200 μL) undergone the above incubation was added with 400 μL of SUV2, and then mixed in a 1.5-mL sample tube to form tetralamellar MEND (T-MEND). Further, T-MEND was added with a 2 mg/mL solution of STR-R8 so that the added STR-R8 amount corresponded to 10 mol % of the total lipid amount of SUV2, and the mixture was incubated at room temperature for about 30 minutes to prepare cationic T-MEND having KALA and R8 on both inner membrane and outer membrane.
- A plasmid encoding luciferase (pDNA, BD Biosciences Clontech) was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL. The 0.1 mg/mL pDNA solution (60 μL) was dropped portionwise with a solution of polyrotaxane (1 mM in terms of amine concentration, 90 μL, average polyethylene glycol chain length: 4,000, number of threaded cyclodextrin: 29, average number of cations in one chain: 46) with stirring to prepare a compaction body of polyrotaxane and pDNA (N/P ratio was 0.5).
- A 3.3 mM solution of cardiolipin (CL, 84 μL) and a 10 mM solution of DOPE (27.5 μL) were put into a glass test tube so as to obtain a CL:DOPE ratio of 1:1. The mixture was added with a 2 mg/mL solution of STR-R8 in such a volume that the added STR-R8 amount corresponded to 20 mol % of the total lipid amount, and a 1 mg/mL solution of STR-KALA in such a volume that the added STR-KALA amount corresponded to 0 or 5 mol % of the total lipid amount, and further added with chloroform to a total volume of 200 μL, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained. This lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect of liposomes (SUV1-0 and 1-5).
- A 10 mM solution of PA (12.2 μL) and a 10 mM solution of DOPE (42.8 μL) were put into a glass test tube so as to obtain a PA:DOPE ratio of 7:2. The mixture was added with a 1 mg/mL solution of STR-KALA in a volume for modifying 0 or 1.5% of the total lipids (0 or 8.3 μL), and further added with chloroform to a total volume of 200 μL, and then the mixture was dried under reduced pressure in a desiccator to evaporate the solvent, and thereby two kinds of lipid membranes were obtained. Each lipid membrane was added with 1 mL of a 10 mM HEPES solution so that the total lipid concentration became 0.55 mM, and the hydrated lipid membrane was exfoliated from the glass test tube by using a bath type sonicator, and then ultrasonicated for 10 minutes by using a probe type sonicator. After the ultrasonication, centrifugation (15,000 rpm, 20° C., 5 minutes) and collection of supernatant were repeated 3 times to collect liposomes (SUV2-0 and 2-1.5).
- The aforementioned compaction body (100 μL) obtained from pDNA and polyrotaxane at N/P=0.5, and each of the solutions of SUV1-0 and 1-5 (200 μL) were mixed in a 1.5-mL sample tube to form bilamellar liposomes (D-MEND-0 and −5). After the formation of D-MEND, a 2 mg/mL solution of STR-R8 was added to each kind of liposomes in such a volume that the added STR-R8 amount corresponded to 5 mol % of the total lipid amount of SUV1, and the mixture was incubated at room temperature for about 30 minutes.
- Further, each solution (D-MEND-0 and −5, 200 μL) undergone the above incubation was added with 400 μL of SUV2-0 or 2-1.5, and mixed in a 1.5-mL sample tube to form tetralamellar MEND (T-MEND). Further, T-MEND was added with a 2 mg/mL solution of STR-R8 in such a volume that the added STR-R8 amount corresponded to 10 mol % of the total lipid amount of SUV2, and the mixture was incubated at room temperature for about 30 minutes to prepare anionic T-MEND having KALA and R8 on both inner membrane and outer membrane.
- Transformed cells were prepared by using the two kinds of T-MEND prepared in the sections (a) and (b) mentioned above according to the method described in Example 1, (e), and expression amount of luciferase in each type of cells was measured according to the method described in Example 1, (f). As a result, in the cationic T-MEND, increase in expression of the encapsulated gene was observed in a KALA modification density-dependent manner (
FIG. 2 ). Further, as also for the anionic T-MEND, the modification of inner membrane and outer membrane with KALA provided 10 times or higher gene expression. In particular, the anionic T-MEND gave gene expression higher than that obtainable with Lipofectamine PLUS, which is a marketed gene transfer reagent. - A plasmid DNA encoding the albumen antigen (ovalbumin) as an antigen was introduced into dendritic cells by using various vectors, and the dendritic cells were collected 24 hours after the transfection, and washed with the medium. Then, 1×104 cells/100 μL of the dendritic cells and 2×105 cells/100 μL of the B3Z (MHC-I) cells were inoculated on a 96-well plate, and co-cultivated for 16 hours. Then, the cells were washed with PBS, added with CPRG buffer (100 μL, obtained by dissolving 5 mM CPRG (Roche Diagnostics), 0.125% NP-40 (Igepal CA-630, SIGMA) and 9 mM MgCl2 in redistilled water, dividing the solution into aliquots in a volume of 1 mL each, and the storing the aliquots at −20° C. under light shielding), and incubated at 37° C. for 4 hours. Then, absorbance of the culture was measured at 595 nm by using Benchmark Plus Microplate Spectrophotometer (Bio-Rad). The absorbance values were normalized with reference to the value obtained for the medium containing only untreated dendritic cells, which was taken as 1. Results are shown in
FIG. 3 . - After the ovalbumin gene was introduced, presentation of the antigen was evaluated. As a result, the marketed Lipofectamine PLUS and the conventional type T-MEND failed to provide antigen presentation superior to that obtained in the control (dendritic cells not introduced with the gene, dotted line). Whilst, antigen presentation was observed for the KALA-modified T-MEND that gave the highest gene expression as shown in
FIG. 2 . From these results, it was demonstrated that the lipid membrane structure of the present invention successfully and highly efficiently introduced the gene into the nuclei of dendritic cells, and the antigen protein expressed from the introduced gene was successfully presented as an antigen on the surfaces of the dendritic cells. - For preparation of core of vector, each of a pDNA solution and a protamine solution was diluted to 0.1 mg/mL with a 10 mM HEPES buffer. A 0.1 mg/mL solution of protamine (150 μL) was dropped portionwise with a 0.1 mg/mL solution of pDNA (100 μL) with stirring to prepare a compaction body of protamine and pDNA (NIP ratio=2.2). As for lipid membrane, a 1 mM solution of DOPE (112.5 μL) and a 1 mM solution of CHEMS (25 μL) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2, the mixture was added with CHCl3 to a total volume of 200 μL, and then the mixture was dried in a desiccator to evaporate the solvent, and thereby a lipid membrane was obtained. This lipid membrane was added with a solution of the compaction body so that the total lipid concentration became 0.55 mM, and added with only STR-R8 in an amount corresponding to 5 mol % of the total lipid amount in the case of R8-MEND, or STR-KALA and STR-R8 in an amount corresponding to 5 mol % of the total lipids in the case of R8/KALA-MEND, and the mixture was left standing at room temperature for 10 minute for hydration, and then ultrasonicated for 1 minute with a sonicator.
- Two days before transfection, the JAWS-II cells were inoculated on a 6-well plate at a density of 4×105 cells/well. The cells were washed with 500 μL of PBS(−), then added with 1 mL of an MEND solution prepared by diluting MEND with αMEM (serum-free, antibiotic-free) to a concentration of 2 μg/mL (in terms of concentration of the plasmid DNA) cell, and left standing at 37° C. in a 5% CO2 incubator. One, three and six hours after the transfection, the cells were washed with 500 μL of PBS(−), and added with TRIzol Reagent (Invitrogen) to a total volume of 1 mL for each sample. The cells were scraped off with a cell scraper, and collected in an Eppendorf tube. The cells were mixed for 1 minute on a vortex mixer and stored at −80° C. For purifying mRNA, each sample was thawed at room temperature, added with 200 μL of chloroform, and mixed for 15 seconds on a vortex mixer. The sample was incubated at room temperature for 3 minutes, and then centrifuged under an environment of 4° C. at 12,000 rpm for 15 minutes. The supernatant was transferred to another Eppendorf tube, and added with 500 μL of isopropanol, and the mixture was incubated at room temperature for 10 minutes. The mixture was centrifuged in an environment of 4° C. at 12,000 rpm for 10 minutes, then the supernatant was removed, the pellet was added with 1 mL of 75% ethanol, and mixed on a vortex mixer, and the mixture was centrifuged (4° C., 12,000 rpm, 4 minutes). The supernatant was removed, the pellet was added with 25 μL of diethyl pyrocarbonate (DEPC)-treated water, the mixture was incubated for 10 minutes, and RNA amount was quantified on the basis of absorbance at 260 nm measured by using Nano Drop (Thermo Scientific).
- Labeled RNA for DNA microarray experiment was prepared by using Quick Amp Labeling Kit one-color (Agilent) according to the protocol attached to the kit. cDNA was synthesized from 500 ng of the total RNA by reverse transcription reaction. Then, cRNA labeled with Cyanine 3 (Cy3)-CTP was prepared from the cDNA by in vitro transcription. In order to remove unreacted Cy3, the labeled cRNA was purified by using RNeasy Mini Kit. For the resulting Cy3-labeled cRNA solution, concentration and Cy3 uptake amount were calculated by using NanoDrop to determine the quality.
- The Cy3 uptake efficiency of the purified labeled cRNA probe (pmol/μg) was calculated from cRNA concentration (ng/μL) and uptake amount of Cy3 (pmol/μL). The calculation method is shown below.
- (1) The cRNA concentration (ng/μL) was calculated in accordance with the following equation.
-
cRNA concentration (ng/μL)=OD260×10*×40 (μg/mL) - *The optical path length of NanoDrop was 1 mm.
(2) The uptake amount of Cy3 (pmol/μL) was calculated in accordance with the following equation. -
Cy3 uptake amount (pmol/μL)=(OD550×10*×1000)/(150 mM−1cm−1) - *The optical path length of NanoDrop was 1 mm.
(3) The Cy3 uptake efficiency (pmol/μg) was calculated in accordance with the following equation. -
Cy3 uptake efficiency (pmol/μg)=Cy3 uptake amount (pmol/μL)/cRNA concentration (ng/μL) - For all the Cy3-labeled cRNA samples, it was confirmed that the yield of cRNA was 1.65 μg or higher, and the Cy3 uptake efficiency was 9 pmol/μg or higher.
- Hybridization of the labeled cRNA to a mouse oligo-DNA microarray (4×44K) was performed by using Gene Expression Hybridization Kit according to the protocol attached to the kit. The labeled cRNA was randomly digested and thereby fragmented, and a hybridization solution was prepared by using 1.65 μg of RNA. A sample was applied to a microarray slide, hybridization was performed at 65° C. and 17 hours, and then the slide was washed with Expression Wash Buffer containing 10% Triton X-102.
- The microarray slide was scanned by using Agilent DNA Microarray Scanner (Agilent Technologies). For the measurement of Cy3, a laser of 532 nm was used. The created TIFF image was read by using Feature Extraction Software, and information of the spots (gene profile) was saved in the form of text file. The resulting expression profile was imported into GeneSpringGX11, and analyzed.
- Among the 41220 genes detected as spots, unreliable genes were eliminated (quality control), and thereby 21995 genes usable as the object of analysis (qualified genes) were extracted.
- When data are imported into the analysis software GeneSpringGX11, control spots including the spots for recognition of the four corners of array are also detected. Therefore these spots were eliminated.
- At the time of the detection of spots, flags for three stages, Present (P), Marginal (M), and Absent (A) (reliability decreases in the order of P, M, and A), are evaluated according to the state of signal, for example, disordered shape, saturation of fluorescence, and the like. The genes were extracted to which the evaluation of Present was given for at least one sample among all the samples.
- Since genes with low expression level might give fluctuation of expression levels even for the same samples, such genes were eliminated. Those genes providing a Raw value of 100 or higher for at least one sample among all the samples were extracted, which value is the absolute value of signal intensity. After the quality control described above was performed, analysis was advanced for the 21995 genes as the object.
- The genes relating to immunity were extracted, and gene expression amounts obtained with 118-MEND and R8/KALA-MEND were compared. The results of this comparison are shown with values of expression amounts of the genes normalized relative to that of untreated cells, which is taken as 1. As a result, it was recognized that the degree of increase in expression of immunity-related genes obtained with R8/KALA-MEND was higher than that obtained with R8-MEND, and the expression of many of the genes increased in a time-dependent manner. From these results, it was revealed that KALA modifying the MEND surface had an adjuvant effect on dendritic cells (
FIG. 4 ). - A lipid thin membrane consisting of EPC/Chol/CHEMS (molar ratio: 70:20:10) was prepared in a glass test tube, added with OVA (5 mg/mL, 10 mM HB) so that the lipid concentration became 10 mM, and hydrated at room temperature for 15 minutes. After the hydration, the lipid membrane was mixed on a vortex mixer, transferred to a 15-mL conical tube, frozen and thawed 5 times. The lipid membrane was subjected to extrusion through a membrane filter of 400 nm, the supernatant was removed by ultracentrifugation (43,000 rpm, 4° C., 30 minutes), and then the pellet was gently rinsed with 200 μL of HBG, and suspended again in an appropriate volume of HBG. According to the procedure described in the following section, the OVA concentration and the lipid concentration were determined. Before use in the experiment, the liposomes were added with STR-R8 (10 mg/mL) or STR-KALA (10 mg/mL) in an amount corresponding to 7.5% of the lipid molar concentration, and the mixture was incubated at room temperature for 30 minutes or more to prepare R8-Lip and KALA-Lip. R8-Lip had a particle size of 189.5 nm, PDI of 0.095 and zeta potential of 47.8 mV, and KALA-Lip had a particle size of 188.4 nm, PDI of 0.317, and zeta potential of 33.7 mV.
- A liposome solution (254) or OVA for preparation of calibration curve diluted with sterilized water to a volume of 1 mL was added with a 0.15% solution of sodium deoxycholate (100 μL), and the mixture was incubated at room temperature for 10 minutes. The mixture was added with a 72% solution of trichloroacetic acid (100 μL), the mixture was centrifuged (3,500 rpm, 4° C., 20 to 30 minutes), and then the supernatant was removed. The resulting pellet was dissolved in a 0.5% SDS solution in 0.1 N NaOH (50 μL), the solution was added with the BCA assay reagent (1 mL), and quantification was performed according to the protocol. The lipid concentration was determined by using Phospholipid C-Test Wako (Wako Pure Chemical Industries).
- R8-Lip or KALA-Lip enclosing 50 μg of OVA was subcutaneously administered (26G needle) to C57BL/6 mice (female, 7 to 9 weeks old). One week after the immunization, target cells prepared by the following method were administered. The spleen was extracted from a naive mouse sacrificed by cervical vertebra dislocation, and the cells were loosened in 3 to 5 mL of the RPMI 1640 medium contained in a petri dish, collected by using a 2.5-mL syringe, then passed through a nylon mesh, and transferred to a 50-mL conical tube. The cells were centrifuged (1600 to 1700 rpm, 4° C., 5 minutes), then the supernatant was removed, and the cells were suspended in 1 mL of the ACK Lysing Buffer (Lonza, Walkersville, Md.), incubated at room temperature for 5 minutes, and thereby hemolyzed. The cell suspension was added with the RPMI 1640 medium (9 mL), then the mixture was centrifuged, and the cells were further washed with the medium (10 mL), then suspended in a volume of 20 mL, passed through a nylon mesh, and transferred to two of 50-mL conical tubes. The cells were counted, centrifuged, and then suspended again in the medium (107 cells/mL). The cell suspension in one of the tubes were added with OVA257-264 peptide (1 mM, final concentration: 5 μM), and this cell suspension was incubated under the conditions of 37° C. and 5% CO2 for 60 minutes. After the cells were washed with medium (10 mL) and PBS (10 mL), the cells pulsed with the OVA257-264 peptide were suspended in PBS containing 5 μM of CFSE (Molecular Probe, CFSEHigh), the cells not pulsed with the OVA257-264 peptide were suspended in PBS containing 0.5 μM CFSE (CFESLow), both at a density of 3×107 cells/mL, and those cells were incubated at 37° C. for 10 minutes. The cells were washed twice with the RPMI 1640 medium (10 mL) and twice with PBS (10 mL), and finally suspended in PBS (5×107 cells/mL). The same amounts of two kinds of the cells stained at different concentrations were mixed immediately before administration, and administered to the immunized mice from the caudal vein (1×107 cells/200 μL/mouse, 26G needle).
- Twenty hours after the administration of the target cells, the spleen was extracted, hemolyzed in the same manner as described above, then washed with the RPMI 1640 medium (10 mL) and PBS (10 mL), and suspended in the FACS buffer (5 mL). The prepared cell suspension was passed through a nylon mesh, and transferred to a FACS tube, and number of CFSE-positive cells was measured with a flow cytometer. There were analyzed 7,500 cells stained at a low concentration (CFSELow). The CTL activity was calculated by comparing the cell numbers of CFSEHigh and cFsELow. Errors between experiments were corrected by using the CFSEHigh/CFSELow ratio of the naive mice.
- Results are shown in
FIG. 5 . The vertical axis represents the CTL activity in terms of percentage of killed cell among the cells served as the target of CTL (cells pulsed with the OVA257-264 peptide). The cells used as the target (CFSEHigh) presented the OVA peptide as MHC class I presentation, and accordingly, the cell-killing effect observed in this evaluation was provided by OVA-specific CTL. - It has been demonstrated that R8-Lip is a carrier capable of inducing specific MHC class I presentation and antitumor activity in vivo (Nakamura, T. et al., Mol. Ther., 16, pp. 1507-1514, 2008). As shown by the aforementioned results, marked improvement in the CTL activity was provided by modifying the liposome surfaces with KALA instead of R8. Although both R8-Lip and KALA-Lip were used without adjuvant, the CTL activity of KALA-Lip was comparable to the CTL activity obtainable by using R8-Lip carrying a CpG sequence-containing oligonucleotide, which is known as an adjuvant. These results support the results of Example 4 that KALA had high adjuvant function, from the viewpoint of the function.
- The following four kinds of plasmid DNAs were prepared: (1) a plasmid DNA containing CpG sequences in the backbone, and also having CpG sequences in a region from the start codon to the stop codon of the luciferase sequence as a marker gene (pcDNA3.1-Luc(+), 425 CpG sequences in total), (2) a plasmid DNA not containing any CpG sequence in both the backbone and the region from the start codon to the stop codon of the luciferase sequence (pCpGfree-Luc(0), 0 of CpG sequence in total), (3) a plasmid DNA containing CpG sequences in the backbone, but not containing any CpG sequence in the region from the start codon to the stop codon of the luciferase sequence (pcDNA3.1-Luc(0), 332 CpG sequences in total), and (4) a plasmid DNA not containing any CpG sequence in the backbone, but containing CpG sequences in the region from the start codon to the stop codon of the luciferase sequence (pCpGfree-Luc(+), 98 CpG sequences in total).
- For the construction of the expression plasmid DNAs containing CpG sequences in the backbone ((1) and (3) mentioned above), the expression vector pcDNA3.1 purchased from Invitrogen was used. Further, for the construction of the expression plasmid DNAs comprising a backbone not containing any CpG sequence ((2) and (4) mentioned above), the expression vector pCpGfree-mcs purchased from Invitrogen was used.
- As for the plasmid DNA (1), the DNA fragment containing the luciferase sequence including CpG sequences was obtained by digesting pGL3-basic vector of Promega with the restriction enzymes HindIII and XbaI. This fragment was introduced into the pcDNA3.1 vector at the HindIII/XbaI sites (pcDNA3.1-Luc(+)).
- As for the plasmid DNA (2), the multi-cloning site of pCpGfree-mcs (BglII-KpnI-EcoO109I-NcoI-NheI) was treated with BglII/NheI, and a double-stranded DNA fragment having ends complementary to the cleavage sites of these restriction enzymes was inserted to create a new multi-cloning site (BglII-PvuII-NcoI-XbaI-NheI) (pCpGfree-NEWmcs,
FIG. 6 ). A gene encoding luciferase not having CpG sequence obtained by treating pORF-Luc::Sh-ΔCpG (Invivogen) with NcoI/NheI was introduced into pCpGfree-NEWmcs at the NcoI/NheI sites (pCpGfree-Luc(+1)). The plasmid DNA prepared by this method had only one CpG sequence after the 12th codon counted from the codons of the luciferase gene (FIG. 7 ). The residual CpG sequence was eliminated by excising a portion of sequence containing the stop codon and the CpG sequence from pCpGfree-Luc(+1) by a DraIII/NheI treatment, and inserting an oligonucleotide having ends complementary to the above restriction enzyme digestion sites, and including a mutation at the site of the CpG sequence. For this operation, the EcoRI site existing immediately downstream of the stop codon was replaced with the EcoRV site (pCpGfree-Luc(0),FIG. 8 ). - The plasmid DNA (3) was prepared by inserting the CpG-free luciferase gene excised from pCpGfree-Luc(0) prepared in the construction of the plasmid DNA (2) by BglII/EcoRV digestion into pcDNA3.1 at the BamHI/RV site (pcDNA3.1-Luc(0)).
- The plasmid DNA (4) was prepared by inserting the luciferase coding gene obtained from pcDNA3.1-Luc(+) prepared in the construction of the plasmid DNA (1) by PmeI/XbaI treatment into pCpGfree-NEWmcs at the PvuII/XbaI digestion site (pCpGfree-Luc (+)).
- The thighbones and the neck bones were extracted from C57BL/6 mice (6 to 8 weeks old) sacrificed by cervical vertebra dislocation, mildly disinfected with 70% ethanol, and then immersed into PBS. Both ends of the bones were cut, and the bone marrow cells were pushed out into the RPMI 1640 medium by using a 1-mL syringe containing the medium (26G needle). The cell suspension was passed through a 40-μm cell strainer (FALCON), and transferred to a 50-mL conical tube. The cell suspension was centrifuged (450 g, 4° C., 5 minutes), then the supernatant was removed, and the cells were dispersed by tapping. Then, the cells were added with ACK Lysing Buffer (1 mL), and they were mixed and left standing at room temperature for 3 to 5 minutes. The cell suspension was added with the medium (10 mL), the mixture was centrifuged, the supernatant was removed, and the cells were further washed twice with the medium (10 mL). Then, the cells were suspended in the medium (10 mL), added to a 10-cm cell culture dish (FALCON), and cultured under the conditions of 37° C. and 5% CO2 for 4 hours or more. Only the floating cells were collected into a 50-mL conical tube by gentle pipetting, and centrifuged, the supernatant was removed, and then the cells were suspended in the medium (10 mL), and counted. The cells were suspended in the medium at a density of 1×106 cells/mL, and added with GM-CSF (final concentration: 10 ng/mL), the cell suspension was dispensed on a 24-well plate (Corning, N.Y.) in a volume of 1 mL/well, and the culture was performed under the conditions of 37° C. and 5% CO2 for two days. After two days and four days, floating cells were removed to leave aggregates of the cells, and the culture was added with a fresh GM-CSF-containing RPMI 1640 medium (1 mL) Floating and weakly adhered cells on the
day 6 to 8 from the start of the culture in the presence of GM-CSF were used for the experiment as immature dendritic cells. The purity was 85 to 90% as determined by evaluation using the CD11c antibody (PE Anti-mouse CD 11c, Clone: N418, BioLegend). - Each of the various plasmid DNAs obtained in the section (a) mentioned above was dissolved in a 10 mM HEPES buffer at a concentration of 0.1 mg/mL. A 0.1 mg/mL protamine solution (150 μL, 10 mM HEPES buffer) was dropped portionwise with the pDNA solution (100 μL) to prepare a compaction body of protamine and the pDNA (N/P ratio was 2.2).
- A 1 mM solution of DOPE (112.5 μL) and a 1 mM solution of CHEMS (25 μL) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2. The mixture was added with a 1 mg/mL solution of stearylated KALA (STR-KALA) in a volume for modifying 5% of the total lipids, and further added with chloroform to a total volume of 200 μL, and the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane. This lipid membrane was added with the compaction body so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and ultrasonicated for 1 minute with a sonicator. The mixture was further added with stearylated KALA (STR-KALA, 1 mg/mL aqueous solution) in such a volume that the added STR-KALA amount corresponded to 5 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes.
- For the preparation of R8-MEND, a 1 mM solution of DOPE (112.5 μL) and a 1 mM solution of CHEMS (25 μL) were put into a glass test tube so as to obtain a DOPE:CHEMS ratio of 9:2, the mixture was further added with chloroform to a total volume of 200 μL, and the mixture was dried under reduced pressure in a desiccator to evaporate the solvent and thereby obtain a lipid membrane. This lipid membrane was added with the compaction body so that the total lipid concentration became 0.55 mM, and the mixture was left standing at room temperature for 10 minutes to allow hydration, and then ultrasonicated for 1 minute with a sonicator. The mixture was added with stearylated R8 (STR-R8, 2 mg/mL aqueous solution) in such a volume that the added STR-R8 amount corresponded to 5 mol % of the total lipids, and the mixture was left standing at room temperature for 10 minutes.
- BMDCs induced by the method described in the section (b) mentioned above were inoculated on a 24-well plate at a density of 4×105 cells/well. The prepared MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.4 μg/well, and the volume was adjusted to 500 μL. The MEND solution was applied to each well, and incubation was performed under an environment of 37° C. and 5% CO2. After 3 hours, RPMI 1640 (containing serum and antibiotic, 500 μL) was added to each well, and the luciferase activity was measured further 21 hours afterward. For the measurement of the luciferase activity, the floating cells were collected together with the medium, and centrifuged (4° C., 500 g, 5 minutes), and the supernatant was removed to collect only the cells. The cells remained in each well and the floating cells collected above were added with Reporter Lysis Buffer (1×), and the both were mixed, adjusted to a total volume of 75 μL, subjected to pipetting, and frozen at −80° C. The sample frozen at −80° C. was thawed, and the cells were scraped off with a cell scraper and collected in an Eppendorf tube. A lysate of the collected cells was centrifuged at 15,000 rpm and 4° C. for 2 minutes, and 50 μL of the supernatant was collected. The resulting supernatant was used for the measurement of the luciferase activity (RLU/mL). Further, proteins were quantified by the BCA method (mg/mL), and the luciferase activity per unit amount of protein (RLU/mg protein) was calculated.
- The results are shown in
FIG. 9 . The left graph shows the gene expression activities obtained in BMDCs with R8-MEND and KALA-MEND using (1) pcDNA3.1-Luc(+) and (4) pCpGfree-Luc(0) prepared in the section (a). When pCpGfree-Luc(0) was used, high gene expression activity-promoting effect was observed with both R8-MEND and KALA-MEND. In particular, it was revealed that when (2) pCpGfree-Luc(0) was enclosed in KALA-MEND, there could be attained a gene expression level enabling antigen presentation expectable on the basis of the results of Examples 2 and 3 performed by using JAWS II (about 107 RUL/mg protein). - When the CpG sequence was eliminated only from the insert ((3) pcDNA3.1-Luc(0)), increase of the gene expression was not observed. Whist, when the CpG sequence was eliminated from the backbone ((4) pCpGfree-Luc(+)), promotion of the gene expression activity was observed. From these results, it was demonstrated that, as for selection of promoter, a combination of the mouse CMV enhancer and the
human elongation factor 1 alpha core promoter was useful for gene transfer into dendritic cell. Further, (2) pCpGfree-Luc(0) in which the CpG sequence was completely eliminated gave higher gene expression compared with (3) pCpGfree-Luc(+), and accordingly, it was demonstrated that a plasmid DNA having the mouse CMV enhancer and thehuman elongation factor 1 alpha core promoter, from which the CpG sequence was completely eliminated, was most suitable for dendritic cells. - An antigen (OVA) gene sequence containing no CpG sequence was designed (DNA sequence of 1161 bp shown in SEQ ID NO: 2 of Sequence Listing), and custom-made synthesis thereof was entrusted (TAKARA). This sequence was subcloned into pCpGfree-NEWmcs at one of the multi-cloning sites thereof, the NcoI/NheI site (pCp Gfree-OVA(0)).
- The dendritic cells isolated and differentiated by the method described in Example 6, (b) were inoculated on a 24-well plate at a density of 4×105 cells/well. KALA-MEND was prepared by using the CpG-free OVA expression plasmid DNA (pCpGfree-OVA(0)) according to the method described in Example 6, (c). MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.4 μg/well, and the volume was adjusted to 500 μL. The MEND solution was applied to each well, and the mixture was incubated under an environment of 37° C. and 5% CO2. After 3 hours, RPMI 1640 (containing serum and antibiotic, 500 μL) was added to each well, and the cells were collected further 21 hours afterward. The floating cells and the adhered cells exfoliated by pipetting in PBS were combined, and collected by centrifugation (4° C., 500 g, 5 minutes).
- When BMDCs were activated by using CpG oligonucleotide as an adjuvant, incubation was conducted at a concentration of 1 μg/mL with BMDCs for 1 hour in RPMI 1640 (serum-free, antibiotic-free) before the transfection of KALA-MEND.
- Fourteen days and seven days before transplantation of antigen (OVA)-expressing tumor cells (E.G7-OVA cells), (1) BMDCs on which only CpG as an adjuvant of DC was acted, (2) BMDCs in which luciferase as a non-antigen protein was expressed by using KALA-MEND, (3) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND, and (4) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND, and which were activated with CpG adjuvant were prepared at a density of 4×105 cells/40 μL in PBS, and the total volume of each was administered to C57BL/6 mice (female, 8 weeks old) at the planta pedis. One week after the second immunization, 8×105 of the E.G7-OVA cells were transplanted to the mice at the left flank, and the tumor volume was periodically measured. The tumor volume (mm3) was calculated in accordance with the equation: tumor volume=major axis×minor axis×minor axis×0.52.
- The results are shown in
FIG. 10 . Decrease of tumor growth was observed after applying the adjuvant stimulation with the CpG sequence compared with the control group administered with PBS, and it was revealed that this effect was obtained at a higher degree with KALA-MEND (non-antigen protein, expressing luciferase). This result supports the results of Examples 4 and 5 showing that KALA-MEND itself had a high adjuvant effect. Further, when the OVA expression plasmid DNA was introduced by using KALA-MEND, almost comparable extremely high tumor preventing effects were observed with or without CpG as an adjuvant. From these results, it was revealed that KALA-MEND successfully imparted an antigen expression level sufficient for exhibiting cytotoxicity activity to BMDCs, and also had an adjuvant effect. - Dendritic cells isolated and differentiated by the method described in Example 6, (b) were inoculated on a 24-well plate at a density of 4×105 cells/well. KALA-MEND was prepared by using the CpG-free OVA expression plasmid DNA (pCpGfree-OVA(0)) according to the method described in Example 6, (c). MEND was diluted with RPMI 1640 (serum-free, antibiotic-free) so that pDNA was to be contained in an amount of 0.8 μg/well, and the volume was adjusted to 500 μL. The MEND solution was applied to each well, and incubation was performed under an environment of 37° C. and 5% CO2. After 3 hours, RPMI 1640 (containing serum and antibiotic, 500 μL) was added to each well, and the cells were collected further 21 hours afterward. The floating cells and the adhered cells exfoliated by pipetting in PBS were combined, and collected by centrifugation (4° C., 500 g, 5 minutes).
- The antigen (OVA)-expressing tumor cells (E.G7-OVA cells, 8×105 cells) were transplanted to C57BL/6 mice (female, 8-weeks old) at the left flank, and on the
day 15 and the day 22 after the transplantation, (1) untreated BMDCs, (2) BMDCs in which luciferase as a non-antigen protein was expressed by using KALA-MEND, and (3) BMDCs in which the antigen protein (OVA) was expressed by using KALA-MEND were each suspended in 40 μL of PBS so that 4×105 BMDCs were contained, and administered to the mice at the planta pedis. The tumor size was periodically measured, and tumor volume (mm8) was calculated in accordance with the equation: tumor volume=major axis×minor axis×minor axis×0.52. - Although antitumor effect was not observed with untreated DCs and the non-antigen protein-expressing BMDCs, superior anti-tumor proliferation effect was observed with OVA-expressing KALA-MEND compared with the untreated mice. Therefore, it was revealed that even if KALA-MEND was administered after a tumor was formed, it successfully provided an antitumor effect.
- The lipid membrane structure provided by the present invention can efficiently migrate into nuclei of any types of cells such as immunocytes including dendritic cells, efficiently release an encapsulated substance such as nucleic acid in the nuclei to allow expression of a polypeptide encoded by such a nucleic acid, and further exhibit an efficient adjuvant effect. Therefore, the lipid membrane structure has a characteristic feature that it enables effective immunotherapy against an arbitrary polypeptide for which immunotherapy is desired.
Claims (14)
1. A lipid membrane structure for delivering a substance into a nucleus of a cell, the lipid membrane structure comprising a lipid membrane that
encapsulates the substance to be delivered, and
is modified with a variant polypeptide of SEQ ID NO: 1 having amino acid residues which consist of the amino acid residues in the amino acid sequence of SEQ ID NO: 1 in which one to three amino acid residues have been deleted, substituted, and/or inserted.
2. The lipid membrane structure according to claim 1 , wherein the lipid membrane structure is a liposome.
3. The lipid membrane structure according to claim 1 , wherein the cell is an immunocyte.
4. The lipid membrane structure according to claim 3 , wherein the immunocyte is a dendritic cell.
5. The lipid membrane structure according to claim 1 , wherein the variant polypeptide of SEQ ID NO: 1 is modified with a hydrophobic group, and the hydrophobic group is inserted into the lipid membrane.
6. The lipid membrane structure according to claim 1 , which has a polypeptide containing a plurality of contiguous arginine residues on the surface.
7. The lipid membrane structure according to claim 1 , which has a polyalkylene glycol on the surface.
8. The lipid membrane structure according to claim 1 , wherein a nucleic acid and a cationic polymer are enclosed in the inside of the lipid membrane structure.
9. The lipid membrane structure according to claim 1 , wherein the substance to be delivered is a nucleic acid encoding an antigen polypeptide to be presented on the surface of an immunocyte.
10. The lipid membrane structure according to claim 9 , wherein the nucleic acid is DNA, and the DNA does not contain CpG.
11. The lipid membrane structure according to claim 1 , wherein the variant polypeptide of SEQ ID NO: 1 has amino acid residues which consist of the amino acid residues in the amino acid sequence of SEQ ID NO: 1 in which one to three amino acids have been deleted.
12. The lipid membrane structure according to claim 1 , wherein the variant polypeptide of SEQ ID NO: 1 has amino acid residues which consist of the amino acid residues in the amino acid sequence of SEQ ID NO: 1 in which one to three amino acids have been substituted.
13. The lipid membrane structure according to claim 1 , wherein the variant polypeptide of SEQ ID NO: 1 has amino acid residues which consist of the amino acid residues in the amino acid sequence of SEQ ID NO: 1 in which one to three amino acids have been inserted.
14. A pharmaceutical composition comprising the lipid membrane structure according to claim 1 as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/617,525 US20150202154A1 (en) | 2010-04-21 | 2015-02-09 | Lipid membrane structure having intranuclear migrating property |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010097888 | 2010-04-21 | ||
JP2010-097888 | 2010-04-21 | ||
PCT/JP2011/059738 WO2011132713A1 (en) | 2010-04-21 | 2011-04-20 | Lipid membrane structure with nuclear transferability |
US201313641812A | 2013-01-22 | 2013-01-22 | |
US14/617,525 US20150202154A1 (en) | 2010-04-21 | 2015-02-09 | Lipid membrane structure having intranuclear migrating property |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/641,812 Continuation US8981044B2 (en) | 2010-04-21 | 2011-04-20 | Lipid membrane structure having intranuclear migrating property |
PCT/JP2011/059738 Continuation WO2011132713A1 (en) | 2010-04-21 | 2011-04-20 | Lipid membrane structure with nuclear transferability |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150202154A1 true US20150202154A1 (en) | 2015-07-23 |
Family
ID=44834230
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/641,812 Expired - Fee Related US8981044B2 (en) | 2010-04-21 | 2011-04-20 | Lipid membrane structure having intranuclear migrating property |
US14/617,525 Abandoned US20150202154A1 (en) | 2010-04-21 | 2015-02-09 | Lipid membrane structure having intranuclear migrating property |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/641,812 Expired - Fee Related US8981044B2 (en) | 2010-04-21 | 2011-04-20 | Lipid membrane structure having intranuclear migrating property |
Country Status (5)
Country | Link |
---|---|
US (2) | US8981044B2 (en) |
EP (1) | EP2572706A4 (en) |
JP (1) | JP5794541B2 (en) |
CN (1) | CN103037840A (en) |
WO (1) | WO2011132713A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6093710B2 (en) | 2011-11-18 | 2017-03-08 | 日油株式会社 | Cationic lipids with improved intracellular dynamics |
WO2015098907A1 (en) * | 2013-12-24 | 2015-07-02 | 国立大学法人北海道大学 | Lipid membrane structure having intranuclear localization property |
JP6551825B2 (en) * | 2014-02-10 | 2019-07-31 | 公立大学法人首都大学東京 | Chromatin structure regulator |
WO2015178343A1 (en) * | 2014-05-20 | 2015-11-26 | 国立大学法人北海道大学 | LIPID MEMBRANE STRUCTURE FOR siRNA INTRACELLULAR DELIVERY |
US20180344641A1 (en) * | 2015-09-04 | 2018-12-06 | C. Jeffrey Brinker | Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications |
JP6966755B2 (en) * | 2015-11-26 | 2021-11-17 | ルカ・サイエンス株式会社 | Recombinant expression vector and lipid membrane structure encapsulating the vector |
US11672866B2 (en) | 2016-01-08 | 2023-06-13 | Paul N. DURFEE | Osteotropic nanoparticles for prevention or treatment of bone metastases |
US11344629B2 (en) | 2017-03-01 | 2022-05-31 | Charles Jeffrey Brinker | Active targeting of cells by monosized protocells |
WO2018230710A1 (en) | 2017-06-15 | 2018-12-20 | 国立大学法人北海道大学 | Lipid membrane structure for delivery into sirna cell |
JP7275111B2 (en) * | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | Method for producing lipid nanoparticles |
WO2019103151A1 (en) * | 2017-11-27 | 2019-05-31 | 国立大学法人千葉大学 | Lipid membrane structure for delivering nucleic acid to within cell |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005056752A2 (en) * | 2003-10-24 | 2005-06-23 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US20130195962A1 (en) * | 2010-04-28 | 2013-08-01 | National University Corporation Hokkaido University | Lipid membrane structure |
US8592210B2 (en) * | 2003-10-01 | 2013-11-26 | Japan Science And Technology Agency | Polyarginine-modified liposome having nuclear entry ability |
US8946380B2 (en) * | 2004-07-12 | 2015-02-03 | Japan Science And Technology Agency | Liposome allowing liposome-entrapped substance to escape from endosome |
US20150245997A1 (en) * | 2012-08-28 | 2015-09-03 | National University Corporation Hokkaido University | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01249717A (en) | 1988-03-30 | 1989-10-05 | Fuji Photo Film Co Ltd | Production of liposome |
JPH0720857B2 (en) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
JP2890316B2 (en) | 1989-07-07 | 1999-05-10 | 科学技術振興事業団 | Materials for biocompatible medical devices |
JP3220180B2 (en) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
EP1161957A1 (en) | 2000-05-26 | 2001-12-12 | Transgene S.A. | Complex for transferring an anionic substance of interest into a cell |
AU4801501A (en) | 2000-05-26 | 2001-11-29 | Transgene S.A. | Complex for transferring an anionic substance of interest into a cell |
CA2445947A1 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
JP3923370B2 (en) | 2002-05-24 | 2007-05-30 | アイリスオーヤマ株式会社 | Stove guard |
JP3415131B1 (en) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | Liposome preparation |
NZ541027A (en) | 2002-12-23 | 2008-04-30 | Dynavax Tech Corp | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
CA2604243C (en) | 2004-04-14 | 2015-11-24 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
JPWO2006101201A1 (en) | 2005-03-24 | 2008-09-04 | 国立大学法人 北海道大学 | Liposomes that can efficiently deliver target substances into the nucleus |
JP5225107B2 (en) * | 2006-02-21 | 2013-07-03 | クロマジェニックス ベー ヴェー | Selection of host cells that express proteins at high levels |
JPWO2007102481A1 (en) | 2006-03-07 | 2009-07-23 | 国立大学法人 北海道大学 | Vector for delivery of target substance into nucleus |
JP2007314526A (en) | 2006-04-27 | 2007-12-06 | Ai Bio Chips:Kk | Membrane protein solubilizing agent and membrane protein solubilizing method |
US20100104623A1 (en) | 2007-02-28 | 2010-04-29 | National University Corporation Hokkaido University Kyoto University And Shionogi & Co Ltd | Agent for enhancing the resistance of liposome against biological component, and liposome modified with the agent |
AU2009273873A1 (en) | 2008-07-24 | 2010-01-28 | Indiana University Research And Technology Corporation | Cancer peptide therapeutics |
-
2011
- 2011-04-20 EP EP11772046.6A patent/EP2572706A4/en not_active Withdrawn
- 2011-04-20 CN CN2011800199166A patent/CN103037840A/en active Pending
- 2011-04-20 JP JP2012511688A patent/JP5794541B2/en active Active
- 2011-04-20 WO PCT/JP2011/059738 patent/WO2011132713A1/en active Application Filing
- 2011-04-20 US US13/641,812 patent/US8981044B2/en not_active Expired - Fee Related
-
2015
- 2015-02-09 US US14/617,525 patent/US20150202154A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592210B2 (en) * | 2003-10-01 | 2013-11-26 | Japan Science And Technology Agency | Polyarginine-modified liposome having nuclear entry ability |
WO2005056752A2 (en) * | 2003-10-24 | 2005-06-23 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US8946380B2 (en) * | 2004-07-12 | 2015-02-03 | Japan Science And Technology Agency | Liposome allowing liposome-entrapped substance to escape from endosome |
US20130195962A1 (en) * | 2010-04-28 | 2013-08-01 | National University Corporation Hokkaido University | Lipid membrane structure |
US20150245997A1 (en) * | 2012-08-28 | 2015-09-03 | National University Corporation Hokkaido University | Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same |
Non-Patent Citations (3)
Title |
---|
Gershon, Hezi et al, "Mode of formation and structural feature of dna-cationic liposome complexes used for transfection." Biochemistry (1993) 32 p7143-7151 * |
Jorgensen, Helle et al, "Mbd1 is recruited to both methylated and nonmethylated cpgs via distinct dna binding domains." Mol. Cell. Biol. (2004) 24(8) p3387-3395 * |
Torchilin, Vladimier P. et al, "Cell transfection in vitro and in vivo with nontoxic tat peptide-liposome-dna complexes." PNAS (2003) 100(4) p1972-1977 * |
Also Published As
Publication number | Publication date |
---|---|
CN103037840A (en) | 2013-04-10 |
US20130122054A1 (en) | 2013-05-16 |
US8981044B2 (en) | 2015-03-17 |
WO2011132713A1 (en) | 2011-10-27 |
EP2572706A1 (en) | 2013-03-27 |
JPWO2011132713A1 (en) | 2013-07-18 |
EP2572706A4 (en) | 2014-02-26 |
JP5794541B2 (en) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8981044B2 (en) | Lipid membrane structure having intranuclear migrating property | |
Guevara et al. | Advances in lipid nanoparticles for mRNA-based cancer immunotherapy | |
JP6716600B2 (en) | Lipid particle formulations for delivery of RNA and water soluble therapeutically active compounds to target cells | |
AU2011353233B2 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
US20110117026A1 (en) | Methods and compositions for the delivery of bioactive compounds | |
US20160151482A1 (en) | Mesoporous alum nanoparticles as a universal platform for antigen adsorption, presentation, and delivery | |
JP6487850B2 (en) | Adjuvant composition, vaccine composition containing the same, and method for producing them | |
EP2687204A1 (en) | Vector for pulmonary delivery, inducing agent, and uses | |
KR20230002300A (en) | lipid nanoparticles | |
JP2017532322A (en) | Stable preparation of lipids and liposomes | |
JP2023520506A (en) | Multilayered RNA nanoparticle vaccine against SARS-COV-2 | |
US10182987B2 (en) | Lipid membrane structure for intracellular delivery of siRNA | |
JPWO2007132790A1 (en) | Liposomes with lipid membranes containing bacterial cell components | |
WO2017030956A1 (en) | Method of inducing a t-cell response to phosphopeptides using nucleic acids encoding phosphopeptide mimetics | |
US20130195962A1 (en) | Lipid membrane structure | |
WO2019103151A1 (en) | Lipid membrane structure for delivering nucleic acid to within cell | |
WO2023111907A1 (en) | Polynucleotide compositions and uses thereof | |
WO2015098907A1 (en) | Lipid membrane structure having intranuclear localization property | |
KR101916941B1 (en) | Polymeric nanoparticle composition for delivering pDNA and preparation method thereof | |
US20230355526A1 (en) | Lipid compositions comprising polynucleotide antigens | |
US20240050477A1 (en) | Lipid nanoparticle | |
麻衣子 | Design of functional polysaccharide-based drug delivery systems for cancer therapy | |
WO2024057237A1 (en) | Lipid nanoparticles | |
Petrović | Design of STING ligand nanoparticles for improved cold cancer immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSIT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARASHIMA, HIDEYOSHI;AKITA, HIDETAKA;SHARIF, MOHAMMAD SHAHEEN;AND OTHERS;REEL/FRAME:035665/0507 Effective date: 20121102 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |